EHV-1: A Constant Threat to the Horse Industry

Fatai S. Oladunni1,2,*, David W. Horohov1 and Thomas M. Chambers1

1 Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, United States, 2 Department of Veterinary Microbiology, University of Ilorin, Ilorin, Nigeria

Equine herpesvirus-1 (EHV-1) is one of the most important and prevalent viral pathogens of horses and a major threat to the equine industry throughout most of the world. EHV-1 primarily causes respiratory disease but viral spread to distant organs enables the development of more severe sequelae; abortion and neurologic disease. The virus can also undergo latency during which viral genes are minimally expressed, and reactivate to produce lytic infection at any time. Recently, there has been a trend of increasing numbers of outbreaks of a devastating form of EHV-1, equine herpesviral myeloencephalopathy. This review presents detailed information on EHV-1, from the discovery of the virus to latest developments on treatment and control of the diseases it causes. We also provide updates on recent EHV-1 research with particular emphasis on viral biology which enables pathogenesis in the natural host. The information presented herein will be useful in understanding EHV-1 and formulating policies that would help limit the spread of EHV-1 within horse populations.

Keywords: EHV-1, abortion, myeloencephalopathy, latency, horse

EHV-1 INFECTION OF HORSES: HOW IT ALL BEGAN

After the discovery of the first virus (Ivanovsky, 1882), 50 years passed before Dimock and Edwards in 1932 first showed that a different kind of microorganism, other than bacteria, was causing contagious epizootic abortion in mares (Dimock and Edwards, 1932). Around the same time, the disease was reproduced by experimental infection of mares with materials from aborted fetuses. Their research indicated that a filterable viral agent was causing abortions in pregnant mares, and they coined the term “viral abortion” to refer to the syndrome (Dimock, 1940). They further identified the gross pathological changes in the aborted fetuses, including intranuclear inclusion bodies in fetal pneumocytes and hepatocytes, and established the term ‘equine abortion virus’ (EAV) was grown in vivo and in vitro (Anderson and Goodpasture, 1942; Doll et al., 1953; Randall et al., 1953), and detailed pathological findings were published (Westerfield and Dimock, 1946). Around the same period, Manninger and Csontos in Hungary also documented the same symptoms of viral abortions as in Kentucky, along with signs of respiratory disease including mild fever (Manninger and Csontos, 1941). They observed the development of symptoms resembling that of mild influenza when bacteriological sterile filtrate from the aborted fetuses with lesions of viral abortion was inoculated into pregnant mares (Manninger and Csontos, 1941). Salyi (1942) also demonstrated that the observed gross and microscopic lesions in fetal abortion material were identical with those reported in Kentucky. In fact, Kress (1941) indicated that the abortion virus is pneumotropic due to the prevalence of bronchopneumonia in horses in contact with aborted...
In vitro, Betaherpesvirus infection slowly progresses in tissue culture and from infected cells is ineffective (Rajcani and Durmanova, 2001). In another study, Rajcani and Durmanova (2001) noted that the virus was a member of the herpes group (Plummer and Waterson, 1963).

**CLASSIFICATION OF HERPESVIRUSES**

Herpesviruses have undergone significant diversification in terms of virion morphology, biological properties, and antigenic properties (Roizman, 1982). The Herpesviridae family members are classified into three subfamilies: *Alphaherpesvirinae*, *Betaherpesvirinae*, and *Gammaherpesvirinae* (Roizman et al., 1981) based on their morphology and biological properties.

**Alphaherpesviruses** are found in a wide range of host species. They undergo an efficient and relatively short replicative cycle, and they establish latency in the sensory neurons or lymphocytes of their hosts (Pellet, 2007). They spread well from cell to cell, but are also easily released from infected cells where they replicate, causing cytopathic effects and the development of intranuclear eosinophilic inclusion bodies (Rajcani and Durmanova, 2001). In vitro, they are often able to infect cells from different animal species. Although in vivo the alphaherpesviruses can infect various host species, there is always a species to which each virus has been adapted (Rajcani and Durmanova, 2001). In such a host, they have the propensity to undergo latency, during which viral pathogenicity is absent. It is suspected that the alphaherpesviruses spread best in the host along the nerves, where intra-axonal transmission predominates (Rajcani and Durmanova, 2001). Members of *Alphaherpesvirinae* subfamily include four different genera; *Simplexvirus*, *Varicellovirus*, *Mardivirus*, and *Iltovirus* (Davison, 2007). EHV-1 is a member of the genus *Varicellovirus*.

Unlike alphaherpesviruses, betaherpesviruses have a limited host range and a long cycle of replication (Riaz et al., 2017). In vitro, members of the *Betaherpesvirinae* only replicate in cells derived from their specific host, further underscoring their narrow host range (Rajcani and Durmanova, 2001). They have a slow replication cycle (running for several days), and their release from infected cells is ineffective (Rajcani and Durmanova, 2001). Betaherpesvirus infection slowly progresses in tissue culture and the infected cells become larger rather than lyse and contain intranuclear inclusion bodies (Roizmann et al., 1992; Rajcani and Durmanova, 2001). Latent infection is established predominantly in monocytes or macrophages (Riaz et al., 2017). Since they do not exhibit preferential neural expansion, they typically exist in leukocytes, reticuloendothelial cells, as well as in renal tubular epithelial cells and the salivary gland ducts (Rajcani and Durmanova, 2001). The viruses in this subfamily are further classified into four genera namely *Roseolovirus*, *Proboscivirus*, *Cytomegalovirus*, and *Muromegalovirus* (Davison et al., 2009).

The members of the subfamily *Gammaherpesvirinae* are slow replicating viruses with lymphotropic properties and limited host range (Rajcani and Durmanova, 2001). Unlike alpha- and betaherpesviruses, gammaherpesviruses initially seem to favor the development of latency in either T or B cells, whereas only a subset of cells supports lytic replication (Ackermann, 2006). There are more homolog genes conserved within members of the subfamily *Gammaherpesvirinae* than members of the other two subfamilies (Riaz et al., 2017). In addition to the genes conserved between herpesviruses, each gammaherpesvirus also contains a set of unique genes which are usually present at the terminal regions of the genome and which are important for viral pathogenesis (Riaz et al., 2017). This subfamily consists of four genera: *Percavirus*, *Macavirus*, *Rhadinovirus*, and *Lymphocryptovirus* (Davison et al., 2009).

**EQUINE HERPESVIRUSES**

To date, all the nine equid herpesviruses isolated belong to either the *alphaherpesvirinae* or *gammaherpesvirinae* subfamilies (*Table 1*). The members of the subfamily of alphaherpesviruses include EHV-1, EHV-3, EHV-4, EHV-6, EHV-8, and EHV-9 (Davison, 2007). The members of the gammaherpesviruses include EHV-2, EHV-5, and EHV-7. Only five of the nine herpesviruses (viz. EHV-1, 2, 3, 4, and 5) can produce disease in horses (Allen et al., 2004). EHV-6 to 8 produce diseases in donkeys and are also known as asinine herpesvirus (AHV, AHV-1 to 3), while EHV-9 or gazelle herpesvirus (GHV) is a pathogen of Thomson's gazelles (Olstlund, 1993; Crabb and Studdert, 1995; Taniguchi et al., 2000).

**EPIDEMIOLOGY AND TRANSMISSION OF EHV-1**

Exposure of horses to either EHV-1 or its close relative EHV-4 occurs very early in life. It has been reported that between 80 to 90% of horses are infected, with either pathogen, by the time they are 2 years of age (Allen, 2002). The great level of antigenic relatedness between EHV-1 and EHV-4 often complicates seroepidemiological findings as a result of a lack of type-specific antibodies and extensive antigenic cross-reactivity that exists in natural infection (Patel and Heldens, 2005). In the early 1990s, evidence became available that the envelope glycoprotein, gG, of EHV-4 elicits a type-specific antibody response, which enabled the differentiation between antibodies.
available data suggest a cyclic but mostly quiet epidemiologic pattern of EHV-1 infection with an infected dam serving as a continuous source of infectious virus particles to its foals between breeding seasons.

**GENOMIC STRUCTURE AND GENE FUNCTIONS OF EHV-1**

The full genome sequence of EHV-1 has been published (Telford et al., 1992, 1998) making information regarding the genomic organization of the virus available. EHV-1 has a linear dsDNA genome of about 150.2 kbp in size with base composition of about 56.7% G+C content (Roizmann et al., 1992). The entire genome is composed of a long unique region (UL, 112,870 bp) flanked by a small inverted repeat sequence (TR<sub>L</sub>/IR<sub>L</sub>, 32 bp), and a short unique region (US, 11,861 bp) that is flanked by a large inverted repeat (TR<sub>S</sub>/IR<sub>S</sub>, 12,714 bp) (Roizmann et al., 1992). The genome contains 80 open reading frames (ORFs) encoding 76 different genes, with four duplicated ORFs present in the terminal repeat sequence (TRS) (Telford et al., 1992; Crabb and Studdert, 1996). The four duplicated ORFs in the EHV-1 genome are ORF 64, 65, 66, and 67 which are present in mixed cases of infection involving both EHV-1 and EHV-4 (Crabb et al., 1992). The antigenic determinants in the carboxyl domain of the gG's of EHV-1 and EHV-4 have been described as useful tools for differentiating between these viruses based on distinct humoral responses that they elicit in their natural hosts (Crabb et al., 1992; Crabb and Studdert, 1993). The annual incidence of EHV-1 is not well defined, as a result of mixed infection with EHV-4 and the ability of both viruses to undergo latency. Latency is an important survival strategy employed by alphaherpesviruses for continuous persistence and dissemination within their natural host population (Whitley and Gnann, 1993). Virus reactivation in an infected host, following latency, could occur at any time to promote a clinical course of the disease and virus shedding.

EHV-1 infection is highly contagious and can easily be acquired by contact with infectious materials, including fomites and aerosols (Lunn et al., 2009). Transmission of the virus to susceptible horses is facilitated by contact with an acutely infected horse or a reactivated virus-shedding horse, or from contact with an aborted fetus or placenta which is rich in infectious virus particles (Allen et al., 2004). Extensive work investigating the transmission cycle of EHV-1 has identified mare and foal populations as important reservoirs enabling virus transmission before and after weaning, with infection in foals occurring within the first 30 days of life (Gilkerson et al., 1999). In a different report, viral shedding was detected in 22 day-old foals even after a widespread vaccination of mares (Foote et al., 2004). Evidence suggests that infected mares, especially those incubating latent EHV-1, serve as a continuous source of viral exposure to foals by horizontal transmission when contact is established between foals and the nursing dam. Broodmares may undergo recrudescence of latent viral infection as a result of stress resulting from pregnancy/parturition, which may expose young foals to EHV-1 infections from mares that are actively shedding the virus (Paillot et al., 2008). Overall, available data suggest a cyclic but mostly quiet epidemiologic pattern of EHV-1 infection with an infected dam serving as a continuous source of infectious virus particles to its foals between breeding seasons.

**TABLE 1 | Known equine herpesviruses.**

| Subfamily of Herpesviridae | Domestic horse (Equus caballus) | Donkey (Equus asinus) | Zebra (Equus grevyi) | Onager (Equus hemionus onager) | Gazelle thomsoni |
|---------------------------|--------------------------------|----------------------|---------------------|-----------------------------|-----------------|
| **Alphaherpesvirinae:**   |                                 |                      |                     |                             |                 |
| (a) Viscerotropic subgroup | Equine herpesvirus 1<sup>a</sup> | pretend herpesvirus 1 | Zebra herpesvirus isolates | Onager herpesvirus isolates | Gazelle herpesvirus 1 |
|                           | (Equid herpesvirus 1<sup>b</sup>) | (Equid herpesvirus 8) |                     |                             |                 |
| (b) Dermatotropic subgroup | Equine herpesvirus 3           | Asinine herpesvirus 3| Zebra herpesvirus isolates | Onager herpesvirus isolates | Gazelle herpesvirus 1 |
|                           | (Equid herpesvirus 3)          | (Equid herpesvirus 6) |                     |                             |                 |
| **Gammaherpesvirinae:**   |                                 |                      |                     |                             |                 |
| Equine herpesvirus 2      | Asinine herpesvirus 2           |                     | Zebra herpesvirus isolates | Onager herpesvirus isolates | Gazelle herpesvirus 1 |
| Equine herpesvirus 5      | (Equid herpesvirus 2)          | (Equid herpesvirus 7) |                     |                             |                 |

Table adapted from Allen et al. (2004). <sup>a</sup>Viruses in the same horizontal row of the table are closely related equid herpesviruses with minor antigenic and genetic variation imposed by natural selection for specific host species. <sup>b</sup>Virus nomenclatures in parentheses are assigned by the Herpesvirus Study Group of the International Committee on Taxonomy and Nomenclature of Viruses (ICTV) (Roizmann et al., 1995; Davison et al., 2000). At this time, the study group has not given ICTV designations to zebra or onager herpesviruses (Davison et al., 2000). A neurotropic herpesvirus isolate from captive gazelle has provisionally been designated Equid herpesvirus 9 (Fukushi et al., 1999).
of these genes’ functions remain unknown but have been predicted to exert major influence in the unique biology of EHV-1 enabling them to adapt to the horse as their natural host (Allen et al., 2004). The genomic details of EHV-1 ORFs including the functions of individual genes are listed in Table 2.

**BIOLOGICAL FUNCTIONS OF EHV-1 PROTEINS**

The structural architecture of a typical EHV-1 particle (Figure 1) is made up of about 30 discrete kinds of polypeptides (Perdue et al., 1974; Turtinen et al., 1981; Turtinen and Allen, 1982; Turtinen, 1984; Meredith et al., 1989). It consists of a genomic core made up of a linear double-stranded DNA neatly packed within an icosahedral capsid of T = 16 with an approximate diameter of 100–110 nm (Riaz et al., 2017). The nucleocapsid, which houses the viral genome, is in itself made up of six proteins encoded by ORFs 11, 12, 13, 14, 15, 23, 24, 40, 46, 49, 51, and 76 (Allen et al., 2004). The capsids of all herpesviruses are similar, comprising 162 capsomers (12 pentons and 150 hexons) (Paillot et al., 2008). The nucleocapsid contains a ring structure made up of 12 portal proteins which enables viral DNA to enter into the capsid (Newcomb et al., 1989; Baker et al., 1990). Although their names differ between herpesvirus families, capsid protein structure and arrangement are preserved across all herpesviruses (Baines, 2011; Brown and Newcomb, 2011).

The amorphous tegument layer, which corresponds to the area between the nucleocapsid and the envelope, comprises about twelve different proteins encoded by ORFs 11, 12, 13, 14, 15, 23, 24, 40, 46, 49, 51, and 76 (Allen et al., 2004). These tegument proteins and enzymes are critically involved in very early events during infection which are required for initiating viral replication (Batterson et al., 1983; Coulter et al., 1993; Paillot et al., 2008). The large tegument protein, UL36, interacts with the capsid's pentons (VP5), which gives an icosahedral symmetry to the innermost portion of the tegument (Machtiger et al., 1980; Newcomb et al., 1996; Zhou et al., 1999). The outermost part of the tegument engages with the envelope membrane of the virus and may sometimes associate with the intravirion part of the integral membrane proteins.

Surrounding the nucleocapsid and the tegument is the viral envelope derived from patches of an altered host-derived cell membrane (Riaz et al., 2017). Embedded in the EHV-1 envelope are twelve different proteins encoded by ORFs 11, 12, 13, 14, 15, 23, 24, 40, 46, 49, 51, and 76 (Allen et al., 2004). These tegument proteins and enzymes are critically involved in very early events during infection which are required for initiating viral replication (Batterson et al., 1983; Coulter et al., 1993; Paillot et al., 2008). The large tegument protein, UL36, interacts with the capsid's pentons (VP5), which gives an icosahedral symmetry to the innermost portion of the tegument (Machtiger et al., 1980; Newcomb et al., 1996; Zhou et al., 1999). The outermost part of the tegument engages with the envelope membrane of the virus and may sometimes associate with the intravirion part of the integral membrane proteins.

The lytic replication cycle of EHV-1 can be summarized as follows: entry into a permissive host cell, viral nucleocapsid uncoating, viral gene expression, viral DNA replication, virion assembly, and virion particle egress (Figure 2). In horses, EHV-1 can infect a diverse range of cell types, including endothelial cells of inner organs, epithelial cells of the respiratory tract, and mononuclear cells in lymphoid organs and the peripheral blood (PBMCs) (Osterrieder and Van de Walle, 2010). Cells are either infected by direct contact with an infectious EHV-1 particle or by cell-to-cell spread following contact with an infected cell (Paillot et al., 2008). Like HSV-1 and most other alphaherpesviruses, including EHV-1, efficient infection is initiated by a relatively unstable attachment to heparan sulfate molecules on the proteoglycan cell surface, mediated by gC and gB, followed by binding of gD to one of the specific receptors on the cell surface (Osterrieder, 1999; Spear, 2004; Azab et al., 2010). The changes in conformation as a result of receptor engagement with gD enables intricate interactions between gB and gH/gL (Spear, 2004). However, for virus entry into host cells, EHV-1 also utilizes a unique receptor that is different from those described for other alphaherpesviruses (Frampton et al., 2005). It has been shown that the Major Histocompatibility Complex I (MHC-I) molecules on some equine cells serve as entry receptors for EHV-1 by binding directly to gD on the viral envelope membrane (Kurtz et al., 2010; Sasaki et al., 2011).

EHV-1 can enter permissive cells either by direct fusion with the host cell membrane or by cell-mediated endocytosis, producing a productive infection in both cases (Frampton et al., 2007). Both entry pathways facilitate the release of viral nucleocapsid and tegument proteins into the infected host cell. As with other alphaherpesviruses, once the virus is released inside the host cell, the tegument proteins dissociate from the nucleocapsid and the capsid is transported along microtubules via dynein, a minus-end-director motor protein, to the nucleus of the cell (Paillot et al., 2008). This mechanism of capsid transport is important especially in the infection of cells such as neurons where the virus may have to travel a long distance away from the site of infection to reach the nucleus (Paillot et al., 2008; Kukhanova et al., 2014). Following the arrival of the capsid at the nucleus, the capsid directly binds to the nuclear pore complex (NPC) and extrudes its content into the nucleus leaving the capsid behind in the cytoplasm (Whittaker and Helenius, 1998; Ojala et al., 2000). For HSV-1, the inner tegument protein UL36 (ICP1/2) which bears a nuclear localization signal (Ojala et al., 2000), together with nucleoporins Nup358 and Nup214 which both bind either directly or indirectly to the capsid, facilitate this process (Kukhanova et al., 2014). Seemingly, all these associations and interactions are necessary for the nuclear import of the viral DNA by importin β (Copeland et al., 2009).
### TABLE 2 | EHV-1 gene products and their functions.

| EHV-1 ORF # | Start  | Stop  | Functional class of HSV homolog (core genes) | Gene products and proposed functions |
|-------------|--------|-------|---------------------------------------------|-------------------------------------|
| 43<sup>†</sup> | 82083  | 83027 | UL18                                        | VP23, involved in intercapsomeric formation with VP19c |
| 42<sup>†</sup> | 77703  | 81832 | UL19                                        | VP5, major capsid protein             |
| 35<sup>†</sup> | 67093  | 65153 | UL26                                        | VP24 and VP21 are products of self-cleavage of UL26, serine protease |
| 35.5<sup>†</sup> | 66142  | 65153 | UL26.5                                      | VP22a, scaffolding protein            |
| 25<sup>†</sup> | 47311  | 46952 | UL35<sup>∗</sup>                            | VP26, capsid protein                  |
| 22<sup>†</sup> | 32916  | 31519 | UL38                                        | VP19c, a component of intercapsomeric complex |
| 57<sup>†</sup> | 102375 | 105020| UL5                                         | DNA helicase-primase, DNA replication |
| 54<sup>†</sup> | 97069  | 99324 | UL8                                         | DNA helicase-primase, DNA replication |
| 31<sup>†</sup> | 55453  | 59082 | UL29                                        | ICP8, Single stranded DNA-binding protein |
| 30<sup>†</sup> | 55184  | 51522 | UL30                                        | DNA polymerase, DNA replication       |
| 18          | 25696  | 24479 | UL42                                        | Double-stranded DNA binding protein, DNA polymerase subunit |
| 7<sup>†</sup>  | 10301  | 7056  | UL52                                        | DNA primase, DNA helicase-primase subunit |
| 56<sup>†</sup> | 102391 | 100130| UL6                                         | Associated with capsids, a subunit of portal complex |
| 44<sup>†</sup> | 84320  | 83148 | UL15                                        | DNA terminase activity, involved in DNA packaging |
| 45<sup>†</sup> | 84480  | 86600 | UL17                                        | Associated with B and C capsids, DNA encapsidation |
| 36<sup>†</sup> | 68975  | 67212 | UL25                                        | Capsid protein, involved in packaging of cleaved viral DNA |
| 32<sup>†</sup> | 59243  | 61570 | UL28                                        | ICP18.5, pac motif-specific DNA binding activity, DNA packaging protein |
| 28<sup>†</sup> | 48763  | 50625 | UL32                                        | Cytoplasmic/nuclear protein involved in DNA cleavage/packaging |
| 27<sup>†</sup> | 48791  | 48369 | UL33                                        | DNA packaging protein involved in capsid assembly |
| 61<sup>†</sup> | 108144 | 107206| UL2<sup>∗</sup>                             | Uracil-DNA glycosylase                |
| 50<sup>†</sup> | 91135  | 92832 | UL12<sup>∗</sup>                            | Alkaline nuclease, involved in viral DNA processing |
| 21<sup>†</sup> | 31276  | 28904 | UL39<sup>∗</sup>                            | ICP6, ribonucleotide reductase large subunit involved with protein kinase activity |
| 9<sup>†</sup>  | 12115  | 11135 | UL50<sup>∗</sup>                            | Deoxyuridine triphosphate             |
| 62<sup>†</sup> | 108843 | 108147| UL1                                         | gL, forms complex with gH to direct viral entry, egress and cell-to-cell spread |
| 52<sup>†</sup> | 94472  | 93120 | UL10<sup>∗</sup>                            | gM, involved in viral cell-to-cell spread |
| 39<sup>†</sup> | 71192  | 73738 | UL22                                        | gH<sub>1</sub>, forms complex with gL to direct viral entry, egress and cell-to-cell spread |
| 33<sup>†</sup> | 61432  | 64374 | UL27                                        | gB, VP7, required for viral entry into a cell, forms a dimer and induces neutralization antibody |
| 55<sup>†</sup> | 100332 | 99421 | UL7<sup>∗</sup>                             | Associated with intracellular capsids, involved in DNA packaging? |
| 51<sup>†</sup> | 92784  | 93008 | UL11<sup>∗</sup>                            | Myristoylated viral protein involved in efficient capsid envelopment and egress |
| 49<sup>†</sup> | 89369  | 91153 | UL13<sup>∗</sup>                            | UL13 PK, tegument protein with protein kinase activity |
| 48<sup>†</sup> | 88947  | 89900 | UL14<sup>∗</sup>                            | Tegument protein with molecular chaperone function |
| 46<sup>†</sup> | 86620  | 87732 | UL16<sup>∗</sup>                            | Tegument protein, located within the intron of UL15, involved in DNA packaging? |
| 37<sup>†</sup> | 69897  | 69079 | UL24<sup>∗</sup>                            | Non-glycosylated membrane-associated protein, neuropathogenic virulence factor? |
| 29<sup>†</sup> | 50618  | 51598 | UL31<sup>∗</sup>                            | Nuclear matrix binding protein, interacts with UL34 |
| 26<sup>†</sup> | 48230  | 47403 | UL34<sup>∗</sup>                            | Associate with inner nuclear membrane, required for nuclear egress |
| 24<sup>†</sup> | 36588  | 46853 | UL36                                        | ICP1/2, largest tegument protein, involved in both uncoating and egress |

(Continued)
TABLE 2 (Continued)

| EHV-1 ORF # | Start   | Stop    | Functional class of HSV homolog (core genes) | Gene products and proposed functions |
|-------------|---------|---------|---------------------------------------------|-------------------------------------|
| 23†         | 33292   | 36354   | UL37                                        | ICP32, tegument protein with nuclear export signal, involved in egress and virion maturation |
| NA          |         |         | UL49.5*                                     | Small membrane-associated protein   |
| 8†          | 10300   | 11037   | UL51*                                       | Palmitoylated virion protein, associated with the Golgi |
| 5†          | 5874    | 4462    | UL54                                        | ICP27, regulation of gene expression at the post-transcriptional level |

**Non-core essential genes**

|                           |         |         |                                    |                                     |
|---------------------------|---------|---------|------------------------------------|------------------------------------|
| 53                        | 94390   | 97053   | UL9                                | Replication origin-binding protein  |
| 12                        | 13595   | 14944   | UL48                               | VP16, tegument protein involved in (immediate early) IE gene expression |
| 64                        | 118591  | 114128  | RS1                                | ICP4, major regulatory protein     |
| 72                        | 131583  | 132791  | US6                                | gD, required for virus entry       |

**Non-core accessory genes**

|                           |         |         |                                    |                                     |
|---------------------------|---------|---------|------------------------------------|------------------------------------|
| 63                        | 111985  | 110387  | RL1*                               | ICP34.5, protein synthesis regulator |
| 60                        | 107116  | 106478  | RL2*                               | ICP0, promiscuous transactivator with E3 ubiquitin ligase domains involved in gene regulation |
| 58                        | 105070  | 105747  | UL3*                               | Nuclear phosphoprotein, involved in nucleolar localization |
| 41                        | 76793   | 77512   | UL4*                               | Nuclear protein, co-localized with UL3 and ICP22 |
| 40                        | 76224   | 74632   | UL20*                              | Virion protein, essential for viral exocytosis |
| 38                        | 69910   | 70968   | UL21*                              | tegument protein, associated with microtubules |
| 20                        | 28859   | 27894   | UL40*                              | Ribonucleotide reductase small subunit, involved in nucleotide metabolism |
| 19                        | 26262   | 27755   | UL41*                              | vhs, virion host shut-off protein, causes non-specific cellular mRNA degradation |
| 17                        | 24234   | 23029   | UL43*                              | Membrane-associated protein         |
| 16                        | 22851   | 21445   | UL44*                              | gC, VP7.5, involved in cell attachment and adsorption, C3b-binding activity |
| 15                        | 21170   | 20487   | UL45*                              | Virion protein, type-II membrane protein involved in virus egress |
| 14                        | 18083   | 20326   | UL46*                              | VP11/12, tegument protein, interacts with UL48 (VP16) |
| 13                        | 15317   | 17932   | UL47*                              | VP13/14, tegument protein, enhances immediate early gene expression |
| 11                        | 12549   | 13463   | UL49*                              | VP22, tegument protein with intercellular trafficking activity |
| 6                         | 7042    | 6011    | UL53*                              | gK, required for efficient viral exocytosis |
| 4                         | 4249    | 3647    | UL55*                              | Nuclear protein, nuclear matrix-binding protein |
| NA                        |         |         | UL56*                              | Type-II membrane protein, associated with intercellular trafficking |
| 65                        | 121368  | 122249  | US1*                               | ICP22, regulatory protein involved in the expression of late genes |
| 68                        | 126275  | 125019  | US2*                               | Virion protein, interacts with cytokeratin |
| 69                        | 126411  | 127559  | US3*                               | US3 PK, has anti-apoptotic activity |
| 70                        | 127681  | 128916  | US4*                               | gG, involved in viral entry and egress |
| 71                        | 129097  | 131490  | US5*                               | gJ, protects from Fas-mediated apoptosis |
| 73                        | 132899  | 134173  | US7*                               | gJL interacts with gE, involved in cell-to-cell spread |
| 74                        | 134406  | 136058  | US8*                               | gE, forms complex with gJ, Fc receptor activity, cell-to-cell spread |
| NA                        |         |         | US8.5*                             | Localized in nucleoli of infected cells |
| 76                        | 136783  | 137442  | US9*                               | Type-II membrane protein, involved in anterograde transport of envelope glycoprotein? |
| 66                        | 122862  | 123572  | US10*                              | tegument protein, tightly associated with capsids |

(Continued)
TABLE 2 | (Continued)

| EHV-1 ORF # | Start | Stop | Functional class of HSV homolog (core genes) | Gene products and proposed functions |
|------------|-------|------|---------------------------------------------|-------------------------------------|
| NA         | US11* |      | Tegument protein, RNA-binding activity, and intercellular trafficking |
| NA         | US12* |      | TAP-binding protein, involved in MHC class I downregulation |
| 1          | 1298  | 1906 | NA Downregulates MHC class I               |
| 2          | 2562  | 1945 | NA Virion virulence factor                  |
| 3          | 2841  | 3614 | Unknown                                     |
| 34         | 64578 | 65060| NA Unknown                                  |
| 47†        | 88917 | 87886| NA Unknown                                  |
| 10†        | 12084 | 12386| UL49A gN, Envelope protein                 |
| 59         | 106416| 105877| NA Virion morphogenesis?                   |
| 67         | 125194| 124376| VP67, co-localizes with nuclear lamin       |
| 75         | 136055| 136447| NA US8A, unknown function                  |

Table was prepared according to available data published in Allen et al. (2004); Nishiyama (2004), Davison (2010), Sarkar (2014), Roizman (1998); Kasem et al. (2010), Telford et al. (1998), and Ma et al. (2012). * Indicates that the gene is dispensable for replication in cell culture; NA, not available; † indicates conserved genes across all mammalian herpesviruses.

Once in the nucleus, the virus can transcribe and replicate its genome, which is a critical step toward virus progeny assembly (Kukhanova et al., 2014). These events lead to the reorganization of the nucleus resulting in increased nuclear size, nucleolus and nuclear domain-10 (ND-10) disruption, chromatin condensation and eventual degradation along with nuclear lamina destruction in late infection (Everett et al., 1998; Simpson-Holley et al., 2005; Callé et al., 2008). Six regulatory proteins expressed as one IE protein (IEP), four early proteins (EICP0, EICP22, EICP27, and IR2) and the late EHV-1 α-gene trans-inducing factor (ETIF or VP16) control the coordinated transcription of EHV-1 genes (Caughman et al., 1985; Gray et al., 1987a; Bowles et al., 1997, 2000; Buczynski et al., 1999; Derbigny et al., 2002). This cascade starts with the tegument VP16 (HSV) homolog protein of EHV-1 acting as a transactivator of an IE (α) gene expression (Purewal et al., 1994). During viral entry, VP16 is carried into the infected cell as a tegument protein and is required for efficient initiation of the lytic replicative cycle of the virus (Lewis et al., 1997; Paillot et al., 2008). The IEP of EHV-1 is encoded by ORF64 and synthesized by host cell RNA polymerase II (Gray et al., 1987a,b). The IEP, a polypeptide of 1487-amino acids (aa), is encoded in each of the two inverted repeats (Grundy et al., 1989) and is essential for virus replication (Garko-Buczynski et al., 1998). It stimulates the expression of heterologous viral promoters during the initial stages of infection, self-regulates its own expression, and acts synergistically with EICP22 and EICP27 to activate the expression of early (E or β) and late (L or γ) viral genes (Smith R.H. et al., 1992; Matsumura et al., 1993; Holden et al., 1995; Zhao et al., 1995). For the transcription of IE genes of HSV-1, the cellular transcription factor Oct-1 binds to a unique canonical sequence: 5′-GyATGnTAATGAATTcYTTGnGGG-3′ (where r is a purine base, y is a pyrimidine base, and n is any base) that overlaps the transcription initiation site of the IE promoter (Macken and Roizman, 1982; Kukhanova et al., 2014). The VP16 protein then interacts with Oct-1 and forms a complex along with the HCFC1 protein which then activates IE gene

FIGURE 1 | Schematic illustration of EHV-1 structure. The basic architecture of EHV-1 consists of an envelope, a tightly woven dsDNA genome enclosed within the capsid, and a tegument layer. Several glycoproteins are present on the surface of the envelope.
is a shortened version (aa 323–1,487) of the IEP (Harty and O’Callaghan, 1991). While IR2 protein can trans-repress the IE gene expression, E and L gene expression cannot be trans-activated due to the lack of an IEP trans-activation domain encoded by amino acid residues 3–89 (Smith et al., 1994). An early nuclear phosphoprotein, about 419 bp, encoded by the EICP0 gene, can trans-activate all types of EHV-1 promoters (Bowles et al., 1997, 2000). Toward its N terminus, the EICP0 contains a conserved cysteine-rich zinc RING finger domain (C3HC4 type) that is important for the activation of the promoters of E (β) and L (γ1 and γ2) genes (Bowles et al., 2000). Although both the IE and the EICP0 proteins of EHV-1 can trans-activate the promoters of EHV-1, their relationship is antagonistic rather than being synergistic (Kim et al., 1999; Bowles et al., 2000). The E genes of EHV-1 encode proteins that are critical for its replication, while the L genes encode the viral structural proteins (Paillot et al., 2008). Following the model of HSV-1 replication, it is now known that once the E proteins are synthesized, viral DNA replication will be started. This involves the interplay of at least seven early proteins including the gene products of UL5, UL8, UL9, UL29, UL30, UL42, and UL52 (Rixon et al., 1996; Davison, 2010; Muylwaert et al., 2011). The initial step of replication of HSV DNA involves the separation of the double-stranded helical structure by ICP8 (UL29) or UL9 proteins in the AT-rich domains of the oriL or oriS origin of replication (Kukhanova et al., 2014). The latter has a copy in the U5 region and two copies in the U3 region of the herpesviral genome respectively (Kukhanova et al., 2014). ICP8 and UL9 bind specifically to ssDNA fragments and the oriS, respectively. This interaction enables the unwinding of the double-stranded helical structure, which then allows for the loading of the helicase-primase complex (UL52, UL8, and UL5) (Kukhanova et al., 2014). Following unwinding of the dsDNA, a complex of processivity factor UL42 and viral DNA polymerase (UL30) synthesize the leading and the lagging strand of the DNA (Kukhanova et al., 2014). This replication occurs in a rolling circle form termed ‘theta form of replication,’ the mechanism of which has not yet been identified. Such replication ensures the formation of long head-to-tail viral DNA concatemers, which are then cut into separate units when viral DNA is packaged into capsids (Roizman and Knipe, 2001).
In addition to the viral factors, other cellular components involved in the replication of the viral genome include DNA ligase, topoisomerase II, and various DNA repair and homologous recombination systems (Weller and Coen, 2012). Another important factor for viral DNA replication is cellular chaperone protein Hsp90 which is essential for intranuclear localization of viral DNA polymerase (Burch and Weller, 2005). Some viral proteins such as uracil N-glycosylase (UL2), deoxyuridine triphosphatase (UL50), thymidine kinase (UL23), alkaline nuclease (UL12), and ribonucleotide reductase (UL39, UL40) participate in nucleotide metabolism, viral DNA synthesis, and DNA repair (Kukhanova et al., 2014).

The production of late (γ) viral genes peaks only after replication of viral DNA has commenced and requires ICP27, ICP8, and ICP4 for an optimal transcription efficiency (Rybachuk, 2009). γ1 (leaky-late) genes such as ICP5 (major capsid protein), ICP34.5, gD, and gB are expressed throughout infection, increasing in transcription only a few fold after replication of DNA has commenced while expression of γ2 (true-late) genes such as UL41 (VHS), UL38, UL36, UL20, gC, and gk, does not occur in significant amounts until after replication of DNA (Rybachuk, 2009). The increase in the expression levels of the late genes, especially those encoding for viral capsids, just after DNA replication has been initiated enables the assembly of progeny virion particles (Kukhanova et al., 2014).

Figure 3 illustrates the pathway involved in herpesviral capsid formation. The assembly of the herpesviral nucleocapsid occurs in the nucleus first as a DNA-free precursor capsid in the presence of scaffolding proteins just before viral DNA encapsidation (Perdue et al., 1976; Lee et al., 1988; Rixon et al., 1988; Paillot et al., 2008). The first step in the capsid formation involves the auto-catalytic assembly of a procapsid following the association of pUL6 and pUL19 with a scaffold made up of conserved pUL26 and pUL26.5 proteins (Mettenleiter et al., 2006). The interaction of these proteins produces an angular portion of the spherical procapsid enhanced by scaffold-scaffold complex formation and triplexes connected to VP5 molecules (Brown and Newcomb, 2011). This is then followed by progressive enlargement of the angular segments, called partial procapsids, to form an enclosed spherical procapsid (Newcomb et al., 1996). Although the procapsid appears to be spherical rather than being polyhedral, it has similar diameter (125 nm) and symmetry (T = 16) as the mature capsid (Brown and Newcomb, 2011). In a similar fashion as the major capsid protein VP5, the portal is incorporated into the developing procapsid by interacting with scaffold proteins to form a complex (Newcomb et al., 2003; Singer et al., 2005; Huffman et al., 2008; Yang and Baines, 2008).

Following the formation of the procapsid, the viral dsDNA genome is then packaged into the capsid (encapsidation) regulated by a three subunit protein known as terminase (Yang et al., 2007). The transport of the virion genome into the capsid marks the exit of the scaffold proteins from the procapsid creating the polyhedral shape of the mature capsid.

The first step in the egress of herpesviruses from the nucleus is the budding phase. During this stage, the capsid, which is surrounded by tegument proteins, acquires an envelope from the nuclear membrane’s inner leaflet (Mettenleiter, 2002). After the viral genome has been packaged and assembled, the nucleocapsid travels within the nucleus with the aid of actin filament (Forest et al., 2005) to establish contact with the inner membrane of the nucleus before primary envelopment (Figure 4). Two viral proteins (pUL31 and pUL34) that are structurally and functionally conserved across herpesviruses (Mettenleiter et al., 2006) are required for the partial dissolution of the nuclear lamina enabling the nucleocapsid to interact with the inner leaflet of the nuclear membrane (Reynolds et al., 2004). Complex formation between these two proteins is essential for the process of primary envelopment, and the lack of either protein stalls the process of nuclear egress tremendously (Chang et al., 1997; Klupp et al., 2000; Roller et al., 2000; Reynolds et al., 2001; Fuchs et al., 2002b). The association of the pUL31-pUL34 complex with nuclear lamins A/C or B (Reynolds et al., 2004; Gonnella et al., 2005) leads to the recruitment of cellular protein kinase C (PKC) which then activates intranuclear lamins A/C and/or B (Muranyi et al., 2002). This complex interaction leads to the breakdown of the nuclear lamin network and the underlying structures (Reynolds et al., 2004; Simpson-Holley et al., 2005), enabling the nucleocapsid to interact with the inner nuclear membrane (Mettenleiter et al., 2006). Although the nucleocapsid acquires its primary envelope through the process of budding from the inner nuclear membrane, there is a striking difference in morphology and protein content when compared to the mature virus (Granzow et al., 2001; Miranda-Saksena et al., 2002). While the primary envelope contains both pUL31 and pUL34 proteins (Fuchs et al., 2002b; Reynolds et al., 2004), the mature virus particle lacks these two proteins demonstrating the differences in composition between primary and matured virions (Mettenleiter et al., 2006). The underlying mechanism by which the enveloped nucleocapsid gain access into the cytoplasm is not well understood. However, it has been shown that entry into the cytoplasm is by direct fusion of the enveloped nucleocapsid with the outer nuclear membrane (Mettenleiter et al., 2006) rather than exit through the nuclear pore. This eventually leads to loss of envelope (de-envelopment) enabling the naked nucleocapsid to acquire tegument proteins once inside the cytoplasm (Mettenleiter, 2002). The phosphorylation-mediated activation of a portion of primary-enveloped virions achieved by the kinase activity of pUS3, a component of these particles in itself, is required for a successful de-envelopment process (Klupp et al., 2001; Reynolds et al., 2002; Schumacher et al., 2005).

Final tegumentation and secondary envelopment occur in the cytoplasmic compartments and require a highly coordinated network of protein-protein interactions (Mettenleiter et al., 2006). The herpesviral proteins interact on one side with the capsid and on the other side with the cytoplasmic tails of the envelope glycoproteins, enabling the structural integrity of the matured virus particle (Mettenleiter, 2002). Two subassemblies, the capsid and the future envelope, are distinct sites where final tegumentation takes place and they efficiently combine to produce the mature virion (Mettenleiter et al., 2006). The capsid proximal proteins consist of conserved pUL36 and pUL37 that contribute to the physical structure of the tegument, the conserved pUL25, and pUS3 which remains closely associated with the capsid (Mettenleiter et al., 2006). Except for pUS3, the
other known components of the inner tegument are preserved across all herpesviruses. Both pUL36 and pUL37 remain closely linked to the capsid until they reach the nuclear pore (Granzow et al., 2005; Luxton et al., 2005) and also serve as a vehicle for intracytoplasmic transport of the capsid during entry and exit of the cytoplasm (Luxton et al., 2006; Wolfstein et al., 2006). Apart from these conserved components, other non-conserved proteins may associate with the inner tegument (Mettenleiter et al., 2006). Strikingly, the abundance of both pUL36 and pUL37 inner tegument proteins in the virion is tightly controlled, unlike those of the outer tegument which vary widely (Michael et al., 2006). Once the outer tegument is added, the virion acquires its secondary envelope. This process of final envelopment occurs within the trans-Golgi network, where glycoproteins together with a subset of tegument proteins (Turcotte et al., 2005), like pUL46, pUL47, and pUL49 for the alphaherpesviruses, are incorporated (Mettenleiter et al., 2006). Two conserved proteins, glycoprotein M and pUL11, that are important for this process have been identified. Glycoprotein M, an envelope protein of the matured virion, helps in retrieving envelope glycoproteins from the cell surface and retaining them at the envelopment site (Crump et al., 2004), while pUL11, a small myristoylated protein, directs envelope protein to future envelope sites (Bowzard et al., 2000; Loomis et al., 2003). At this stage, complex associations between many different proteins are required for the ultimate assembly of a mature herpes virion (Fuchs et al., 2002a; Chi et al., 2005; Mettenleiter, 2006). Following the development of a secondary envelope, a mature herpesviral particle enclosed within an intracellular vesicle is formed and transported to the cell membrane (Mettenleiter et al., 2006), by anterograde cellular microtubule-dependent molecular motor kinesin (Guo et al., 2010). The fusion between this intracellular vesicle and cell membrane enables the release of the newly produced virion particles outside of the cell (Mettenleiter et al., 2009).

**ESTABLISHMENT OF LATENCY**

EHV-1, like other herpesviruses, can establish a lifelong presence within cells of a susceptible host following primary infection. The initial stages of EHV-1 infection of the epithelial upper respiratory tract (URT) are accompanied by progression into a stage of latency in which infected horses show no clinical signs of the disease, virus shedding, or cell-associated viremia (Allen...
FIGURE 4 | Herpesvirus egress pathway. Following intranuclear encapsidation of the virus genome, the herpesviral nucleocapsid will bud through the inner nuclear membrane resulting in perinuclear localization of an enveloped primary virion. This primary envelope becomes lost (de-envelopment) as the virus translocates into the cytosol where the nucleocapsid acquires tegument proteins. Final (secondary) envelopment then occurs in the cytoplasm derived from the trans-Golgi network and the enveloped virion is transported in a vesicle to the plasma membrane for release.

et al., 2004; Paillot et al., 2008). While productive infection by EHV-1 leads to active viral gene expression in a well-coordinated manner as described above, the hallmark of latency is the restriction of viral gene expression which culminates in failure to synthesize viral factors and absence of infectious virus particles. The primary site of latency establishment by EHV-1 in the horse has been a subject of debate. While some studies have demonstrated that latency of EHV-1 occurs in lymphocytes, both circulating and those in draining lymph nodes (Welch et al., 1992; Edington et al., 1994; Chesters et al., 1997), others have shown that the sensory nerve cell bodies within the trigeminal ganglia are the preferred primary site of latency for EHV-1 (Slater et al., 1994b; Baxi et al., 1995). While about 80% of CD5+/CD8+ T- lymphocytes have been demonstrated as the major lymphoid cell population enabling latency of EHV-1, a smaller sub-population of 20% CD5+/CD8−/CD4− cells have also been found to support latency (Smith et al., 1998). Regardless of the site of establishment, it appears that the ability of EHV-1 to pass into a latency stage is a deliberate biological behavior that the virus utilizes to perpetuate itself in the host and this enables viral spread to susceptible horses upon reactivation. During latency, the expression of the EHV-1 genome is suppressed and only the latency-associated transcripts (LATs) antisense to either the immediate-early viral gene (ORF 64) or a regulatory early gene (ORF 63) are present in infected cells (Baxi et al., 1995; Chesters et al., 1997; Paillot et al., 2008). The exact molecular and physiological mechanisms that direct latency in EHV-1 infected horses are poorly understood. However, latency has been much better studied in HSV-1 and findings reveal that the major detectable transcript lies within an 8.6-kb sequence antisense to and overlapping the immediate-early (IE) gene IE-1 (ICP0) (Chesters et al., 1997). The LAT itself is a 2.0 kb transcript lacking a polyadenylation site and found mostly in the nuclei of infected neurons (Chesters et al., 1997). In HSV, LAT can promote latency but is dispensable for maintenance or viral reactivation from latency (Efstathiou and Preston, 2005).

It has been shown that reactivation of latent EHV-1 is possible following exposure to stressful conditions such as transportation, handling, re-housing, and weaning or following the administration of corticosteroids (Burrows and Goodridge, 1984; Edington et al., 1985; Slater et al., 1994a). The fact that EHV-1 has been experimentally reactivated from cases of both natural and experimental infection following administration of immunosuppressant (Edington et al., 1985, 1994; Slater et al., 1994b) suggests that horses harboring latent EHV-1 could periodically shed the virus following exposure to stressors. Viral factors, such as the thymidine kinase, have been shown to modulate EHV-1 virulence and latency (Xie et al., 2019).

As a result, the cycle of persistent latent infection followed by reactivation of the virus with shedding into nasal mucus may enable virus propagation and disease spread to susceptible uninfected horses. In certain instances, the characteristic respiratory illness followed by nasal shedding is absent following EHV-1 reactivation and such horses are therefore silent virus shedders (Edington et al., 1985). It has been reported that during the reactivation process a small fraction of lymphocytes carrying the latent EHV-1 genome can progress toward active
transcription resulting in DNA revival and fusogenic viral glycoprotein expression on their cell surfaces ultimately leading to active virus replication (Edington et al., 1985; Slater et al., 1994a). The fine details of the molecular mechanism underlying reactivation of EHV-1 from its quiescent state to a lytic productive infection remain elusive. However, it has been suggested that the IE gene promoter of a latent EHV-1 can be trans-activated by the presence of another equine herpesvirus, EHV-2, in a mixed infection (Purewal et al., 1992).

THE ECONOMIC IMPORTANCE OF EHV-1 TO THE US HORSE INDUSTRY

About 10 million of the world horse population reside in the United States (Smith R.H. et al., 1992. FAOSTAT: Livestock 2017). The horse industry is a large and economically diverse industry which accommodates a wide array of economic activities. It has been reported that in the US, the horse industry generates annually an income of about $102 billion when considering both direct and indirect spending (Anonymous, 2005). With such enormous revenue generated from the horse industry in the US, an outbreak of any disease affecting its horse population is likely to perturb the economic health of the industry. The relevant effects of EHV-1 on the equine industry have been summarized (Lunn et al., 2009). Firstly, EHV-1 outbreaks may result in cases of subclinical to mild respiratory illness especially with young athletic horses developing pyrexia and thus lead to interruptions of training schedules. This can be considered as the least significant economic effect of EHV-1 on the horse industry. Secondly, the incidence of abortion in pregnant mares during the third trimester of gestation results in major losses to the growth of the industry. Thirdly, neurologic outbreaks of the disease, equine herpesviral myeloencephalopathy (EHM), are very severe and may lead to deaths of horses, disruption of breeding or training schedules, cancelation of horse events, and extensive movement restrictions with consequent management difficulties at racetracks, training facilities, and other horse shows. Even though horses may recover from the disease, their productivity is usually compromised, and the money expended in the care and management of horses infected with EHV-1 may run into several thousands of dollars depending on the farm size.

PATHOGENESIS AND DISEASE MANIFESTATIONS

The pathogenesis of EHV-1 infection has been described by the study of an experimental model of infection using the EHV-1 strain, AB4 (Paillot et al., 2008). EHV-1 is a highly contagious viral pathogen of horses usually transmitted following direct contact with infectious materials such as nasal discharges and materials from aborted fetuses or indirectly by fomites (Allen et al., 2004). In horses lacking protective mucosal immunity, nasal and mucosal epithelial cells are the primary sites of replication of EHV-1 (Patel et al., 1982; Kydd et al., 1994a; Rusli et al., 2014). Subsequently, virus replication is quickly followed by erosions of epithelial cells of the URT due to necrosis and inflammatory cellular responses which ultimately lead to nasal shedding of infectious virus (Paillot et al., 2008). Once in the URT, EHV-1 can spread quickly utilizing and hijacking infected mucosal monocytes to invade the deeper connective tissues (Gryspeerdt et al., 2010; Vandekerckhove et al., 2010). Consequently, EHV-1 can cross the basement membrane, invading the reticuloendothelial system and the lymphatics to infect circulating leucocytes and endothelial cells of blood vessels (Gryspeerdt et al., 2010). Within 24 h of infection, infected mononuclear leucocytes could be found present in the sinuses and parenchyma of respiratory tract-associated lymphoid organs (Kydd et al., 1994a). Here, EHV-1 undergoes a second round of replication and viral particles are significantly amplified culminating in infected leucocytes escaping, via the efferent lymph, into the blood-vascular circulation leading to a state of cell-associated viremia (Patel et al., 1982; Dutta and Myrup, 1983; Scott et al., 1983; Edington et al., 1986). The ability to establish viremia is key and defines the outcome of EHV-1 pathogenesis produced from the second round of replication. Viremia facilitates the spread of the virus to tertiary replication sites in the endothelium of the pregnant uterus or the central nervous system (Allen et al., 2004) leading to two clinically important sequelae of EHV-1 respiratory infection, namely abortion or a neurological syndrome (Mumford et al., 1994; Slater et al., 1994a).

Respiratory Disease

EHV-1 is a leading etiological agent of respiratory disease in horses, producing upper airway infection primarily in young horses. The virus is highly ubiquitous among horse populations causing an epidemic disease in young horses and having an estimated prevalence rate of 80 – 90% in horses below 2 years of age (Allen, 2002). Following contact with an infectious viral particle, the mucosal epithelial cells of the URT of an infected horse are the prime target of EHV-1 where the virus undergoes its first round of replication (Figure 5). Within 12 h post-infection, progeny virus and viral antigen are detectable in the respiratory epithelium of an infected horse (Paillot et al., 2008) and the virus can quickly spread to the respiratory endothelium within 24 h of infection (Kydd et al., 1994b). Besides, circulating mononuclear cells and endothelial cells of blood vessels are also infected as a result of viral cell-to-cell spread, thus facilitating viral dissemination throughout the body (Paillot et al., 2008; Vandekerckhove et al., 2011).

Subsequently, there is erosion and necrosis of the respiratory epithelium, release of proinflammatory cytokines, and shedding of infectious virus particles within the first week of the respiratory disease (Paillot et al., 2008). Depending on the pathogenicity of the EHV-1 strain, the incubation period of infection may either be short (1–3 days) (Gibson et al., 1992a,b,c) or prolonged (up to 10 days) (Ostlund, 1993). EHV-1 primarily results in respiratory tract disease (rhino-pharyngitis and tracheobronchitis) (Allen, 2002) presenting a clinical picture similar to other viral pathogens of the respiratory tract of the horse (e.g., equine arteritis virus, influenza virus, adenovirus, or rhinovirus) (Allen, 2002). Although most of these respiratory
infections are subclinical or mild, and a large number of foals seroconvert without clinical signs, some young naïvely exposed horses may show visible signs of nasal discharge and coughing (Allen, 2002; Allen et al., 2004). Previously exposed horses have immune memory that helps reduce the clinical severity of the disease and are infected for only a short duration (Kydd et al., 1994a,b; Allen, 2002). Based on the age and the level of immunity in the infected horse, the respiratory infection may be mild in older horses, pregnant mares, and previously exposed horses, even following virus reactivation from latency (Allen et al., 2004). Experimental infection using the virulent Ab4 strain of EHV-1 revealed a biphasic pattern of pyrexia which may last for up to 10 days (Gibson et al., 1992a,b,c). The clinical picture of the disease includes moderate depression and anorexia, conjunctivitis and serous ocular discharge, and notably a serous nasal discharge which rapidly progresses to mucoid and mucopurulent discharge (Allen et al., 2004). The presence of mucopurulent discharge can be associated with a secondary bacterial infection which may exacerbate the disease. There is progressive lymphadenopathy mainly affecting submandibular lymph nodes (LN) (Allen et al., 2004) and evidence of leukopenia (both lymphopenia and neutropenia) have also been reported (Doll et al., 1954b; Lunn et al., 1991; McCulloch et al., 1993). Occasionally, retropharyngeal LN may also be enlarged and become palpable for some days (Allen et al., 2004). LN may reach maximum size between 3 to 10 days and may remain enlarged for several weeks following infection (Allen et al., 2004). In some infected foals, EHV-1 may reach the lungs inducing bronchopneumonia as a result (Crabb and Studdert, 1996).

While infected horses may occasionally cough, the severity and duration of clinical signs of the disease in a horse are influenced by proper hygiene and rest from exercise or training (Mumford and Rossdale, 1980). Generally, the upper respiratory tract disease (URTD) associated with EHV-1 infection
is short-lived and of acute course with clinical symptoms and nasal shedding of the virus manifesting for the first few days following infection (Allen, 2002). Although the prognosis of URTD from EHV-1 is good with spontaneous recovery by the end of the second week of onset of infection, severe bacterial co/secondary infection can prolong the disease and undermine the prognostic chances of survival (Allen, 2002). Upon recovery from URTD caused by EHV-1, some horses may develop non-specific bronchial hypersensitivity, resembling chronic obstructive pulmonary disease, which may hinder their performance and lead to poor performance syndrome (Mumford and Rossdale, 1980).

**Abortion, Neonatal and Perinatal Disease**

The associated health implications of EHV-1 extend beyond causing URTD since the virus may invade other organs causing more pronounced disease manifestations (Allen, 2002). One of the sequelae of EHV-1 URTD is abortion in which the virus travels to distant sites such as the reproductive tract by cell-associated viremia or latent viral reactivation (Allen et al., 1999) thereby inducing premature detachment of the fetus from the placenta, stillbirth, or weak neonatal foals (Reed and Toribio, 2004). Pregnant mares infected with the virus may abort spontaneously without prior signs of primary URTD by EHV-1 (Dimock, 1940; Dimock et al., 1942; Bryans and Allen, 1986; Smith K. et al., 1992; Mumford et al., 1994). The important roles exerted by host immune and inflammatory responses, and vascular coagulation cascades mediating EHV-1-induced abortion have not been fully elucidated (Allen et al., 2004). However, infection of the endothelium of a pregnant uterus by EHV-1 results in vasculitis particularly affecting the small vascular networks of the glandular endothelia of microcotyledons (Jackson et al., 1977; Edington et al., 1991; Smith K. et al., 1992; Smith et al., 1993). Within 9–13 days post-infection, endothelial cell infection becomes widespread resulting in multifocal vasculitis of the affected blood vessels (Allen et al., 2004). The appearance of microthrombosis within blood vessels may sometimes promote thrombo-ischemic necrosis of the cotyledons and intercotyledonary stroma causing the fetus to detach from the placenta (Smith et al., 1993). The aborted fetus dies of anoxia following a rapidly progressive separation of the placenta-endometrium immediately before fetal expulsion (Allen, 2002). Widespread vascular endothelial damage may cause the fetus to be aborted even before any detectable level of virus is transferred via the placenta to the fetus (Smith K. et al., 1992).

Experimentally induced abortions by EHV-1 in which virus was not recovered from the aborted fetuses have been reported to be as a result of either maternal stress or pyrexia (Gleeson and Coggins, 1980; Carrigan et al., 1991). In another experimental study, the extent of uterine vasculitis and intercotyledonary necrosis corresponds to reduced viral burden in the aborted fetus with fewer lesions found in mares aborting virus-positive fetuses (Smith et al., 1993, 1997). The severity of disease leading to abortion is usually dependent on certain factors including the virulence of the EHV-1 strain involved, the level and magnitude of viremia, and the hormonal state of the pregnant mare. More virulent strains of EHV-1 such as Ab4 have been reported to produce more pathologies including abortion at a higher rate in pregnant mares than the less virulent strains like V592 (Mumford et al., 1994). The pathogenesis of EHV-1-induced abortion by the less virulent strains of EHV-1 is not clear but it appears that those strains have reduced affinity for endothelial cell invasion (Allen et al., 2004). It has also been reported that the magnitude rather than the duration of viremia is a significant correlate of abortion induced by EHV-1 during an experimental challenge (Mumford et al., 1994). Similarly, hormones such as prostaglandin and chorionic gonadotrophin (CG) released by the placenta have been reported to exert some roles in reactivating the virus and initiating abortion (Allen et al., 2004; Paillot et al., 2008). EHV-1 may be transferred by the placenta to the fetus thereby inducing multi-organ pathologies. EHV-1-infected fetuses that are born alive become sick either at conception or within 1–2 days of birth (Bryans et al., 1977; Dixon et al., 1978; Hartley and Dixon, 1979; McCartan et al., 1995). However, such foals rapidly deteriorate and soon die. Infected foals develop severe respiratory distress, which increases the risk of viral pneumonia or bacterial co/secondary infection, leading to respiratory failure within a few days (Crabb and Studdert, 1996; Allen et al., 1999). Foals infected with EHV-1 can also show signs of gastrointestinal disorder (manifested in diarrheic excretion) and neurological deficiencies such as visual and vestibular defects (Dixon et al., 1978). Prognosis is grave and no treatment is available to stop the fatal clinical deterioration of health in infected foals. It has been suggested that congenital defects resulting from EHV-1 infection may be epizootic, especially during sporadic outbreaks of EHV-1-induced abortion (Allen, 2002).

**Myeloencephalopathy**

Another clinical sequel of EHV-1 respiratory disease is the neurological form of the disease termed EHM, sometimes appearing after 1 week of infection (Crabb and Studdert, 1996; Donaldson and Sweeney, 1997; Wilson, 1997; Pusterla et al., 2009). Neurologic symptoms may be simultaneously present with or without respiratory disease or abortion (Timoney, 1992; Hahn et al., 1999). Fundamentally important in the spread of EHV-1 is cell-associated viremia which effectively disseminates the virus to the vascular network of the CNS. The intracellular localization of EHV-1 during infection protects it from the neutralizing effect of circulating antibody, enabling an efficient spread of the virus throughout the body, including to the CNS, even when high levels of antibodies are present (Bryans, 1969). Like other members of *Herpesviridae*, EHV-1 can be transmitted directly from cell to cell independent of an extracellular phase (Allen, 1986). The vascular endothelium of the CNS serves as the preferred site for EHV-1 replication following the transfer of the virus from circulating mononuclear cells (Wilson, 1997). Endothelial cell invasion and the accompanying inflammation of the vasculature of the CNS is central to the neurological syndrome caused by EHV-1 (Jackson and Kendrick, 1971; Jackson et al., 1977; Patel et al., 1982; Edington et al., 1986). The vasculitis of the endothelium resulting from EHV-1 infection may be as a result of two different events; first, direct damage of the vascular endothelium during EHV-1 replication, and second, immune complex formation between
EHV-1 and antibody (Arthus-type reaction) (Reed and Toribio, 2004). Common hallmarks of the neurological form of EHV-1 are the development of vasculitis with or without hemorrhage, and thrombo-ischemic necrosis of the microvasculature of the brain or CNS (Allen et al., 2004). The observed clinical signs in infected horses are a culmination of the vasculitis, edema, hemorrhage, ischemia, and necrosis resulting from the viral predilection for vascular endothelium (Reed and Toribio, 2004). Indeed, the ability of certain EHV-1 strains to inflict damage on the CNS is not reflective of their neurotropic trait but instead an endotheliotropic attribute (Jackson and Kendrick, 1971; Jackson et al., 1977; Edington et al., 1986, 1991; Nowotny et al., 1987).

However, the observation of neural lesions and chorioretinopathy during experimental infection of specific pathogen-free ponies indicates that at least some EHV-1 strains may be neurotropic (Slater et al., 1992). There seems to be no satisfactory scientific explanation for the variable incidence of EHM and different clinical manifestations observed during outbreaks of EHV-1 (Whitwell and Blunden, 1992; McCartan et al., 1995). Several factors including sex, age, immune status of the horse, the reproductive status of the mare (including the stage of gestation), the severity of infection, the type of strain, and perhaps the route of transmission determine the clinical picture of EHV-1 infection (Studdert et al., 1984; Whitwell and Blunden, 1992; McCartan et al., 1995).

Clinical signs of the neurologic disease may become apparent within 2 weeks of URTD or may occur without any antecedent sign of the disease (Wilson, 1997). The clinical presentations are highly variable and widespread depending on the site of neurologic impact and usually peak between 2 and 3 days of onset (Allen et al., 2004). Generally, there is anorexia, pyrexia, edema of the distal limb, abortion, fetal death, or neurologic syndrome, and these are variable in different horses (McCartan et al., 1995). The extent of neurological dysfunction ranges from temporary ataxia with an abnormal gait to complete paralysis. Conscious proprioceptive deficits have also been observed (Allen et al., 2004). The neurological disorders affect mainly the hind limbs, although complete recumbency or tetraplegia have also been observed (Kohn and Fenner, 1987; McCartan et al., 1995; Allen et al., 2004). In some cases, there are signs of bladder dysfunction with accompanying urinary incontinence and scalding of the perineal area or urinary retention which may lead to colic (Franklin et al., 1985). Horses that are non-recumbent have a good prognosis unlike recumbent horses that may suffer additional complications such as pneumonia, colic or bladder rupture (George, 1990; McCartan et al., 1995; Allen et al., 2004) and are generally euthanized.

Recent Outbreaks of EHM
Outbreaks of disease resembling EHM, among domestic horse populations, have been recorded for centuries. Today, a resurgence in the number of EHM cases across the world has necessitated the classification of this syndrome as an emerging disease of the horse. According to the Center for Emerging Issues report of 2007, EHM satisfies the requirement for an emerging viral disease premised on (1) the more virulent nature of the circulating EHV-1 strains than previously reported and (2) increased incidence of the disease with a heightened case-fatality rate (APHIS and USDA, 2008). Increased outbreaks of EHM were reported not only in North America and Europe, but also in Africa, Oceania, and Asia (Henninger et al., 2007; Grysepeert et al., 2011; Tsujimura et al., 2011; Burgess et al., 2012; Pronost et al., 2012; Traub-Dargatz et al., 2013; Walter et al., 2013; Estell et al., 2015; van Galen et al., 2015; McFadden et al., 2016; Negussie et al., 2017). The recent increased incidence of EHM during EHV-1 outbreaks supports the observation that the currently circulating neuropathogenic EHV-1 strain has evolved into a more pathogenic strain producing a higher rate of morbidity and mortality than previously (APHIS and USDA, 2007). EHM has been associated with an A2254→G2254 mutation in ORF 30 encoding the DNA polymerase of EHV-1. Generally, non-neuropathogenic strains possess asparagine at position 752 of DNA polymerase which is substituted by aspartic acid in neuropathogenic strains (Nugent et al., 2006; Goodman et al., 2007). This relationship is strong but not always true in field outbreaks, and other factors may contribute to neuropathogenicity (Lunn et al., 2009; Pronost et al., 2010). Approximately, 14 percent to 24 percent of EHV-1 strains from horses displaying clinical signs of EHM lack this genetic indicator suggesting that the so-called non-neuropathogenic genotype of EHV-1 can also cause EHM (Nugent et al., 2006; Perkins et al., 2008). This disease condition is a major concern for the horse industry considering its negative impact on the economic health of the industry.

The associated risk factors for this increased incidence of EHM are still poorly defined. However, outbreaks have been reported mostly at places such as racetracks, riding schools, and veterinary hospitals where horses from different origins congregate (Kohn et al., 2006; Henninger et al., 2007; Traub-Dargatz et al., 2013). The high stocking density of stabled horses during events such as horse racing may facilitate the quick spread of EHM by direct contact when outbreaks occur. International movement of horses has also played a role in some recent outbreaks of EHM (APHIS and USDA, 2007; Barbic et al., 2012). Other factors that have been reported to facilitate increased incidence of EHM include poor biosecurity measures and presence of stressors (Traub-Dargatz et al., 2013; Pusterla and Hussey, 2014) along with other ill-defined environmental and host factors (Perkins et al., 2009). Importantly, the mutant EHV-1 (G2254) is now widely distributed within horse populations which implies a tendency toward the increased incidence and severity of recent EHM outbreaks.

Ocular Disease
Occasionally and particularly in foals, respiratory tract infection with highly pathogenic EHV-1 strains is associated with severe ocular lesions such as chorioretinitis or uveitis (Del Piero and Wilkins, 2001). Within 3–5 weeks of URTD by EHV-1, foals may develop three distinct types of chorioretinal lesions (focal, multifocal or diffuse) without uveitis (Slater et al., 1992). Although the first report of EHV-1 associated chorioretinitis was in llamas and alpacas (Rebhun et al., 1988; House et al., 1991), this condition has also been documented in natural outbreaks of paralytic EHV-1 infection involving a mare and foal (Whitwell and Blunden, 1992). More recently, an incidence rate
of 50–90% of horses was shown to develop chorioretinal lesions during an experimental challenge with EHV-1 (Hussey et al., 2013). Like the pathogenesis of EHV-1 induced abortion and neurologic syndromes, replication of EHV-1 in the vasculature of the chorioretina may result in ischemic necrosis resulting in visual impairment (Slater et al., 1995). Apart from chorioretinitis, uveitis is another ocular condition seen in some foals following outbreaks of EHM in mares and stallions (McCartan et al., 1995). Young foals that come in close contact with EHM-infected mares and stallions are at high risk of developing ocular disease associated with EHV-1 (McCartan et al., 1995).

### EHV-1 INTERACTIONS WITH THE HOST IMMUNE SYSTEM

Several efforts over the decades have been channeled toward understanding and characterizing the protective host immune response against EHV-1 which could be exploited to advance diagnostic approaches and vaccine development. However, despite over 80 years since EHV-1 was first recognized, we do not yet fully understand how the virus’ interaction with the host immune response can be harnessed for the development of more effective immunotherapy.

Following experimental infection of horses with a virulent strain of EHV-1, viral components were immediately detected in the regional LN of the respiratory tract within 12 hpi (Kydd et al., 1994a,b). This indicates that the virus has close interaction with the host immune system during early infection, and triggers an immediate host response consisting predominantly of inflammatory cytokines. Johnstone et al. (2016) recently reported the upregulation of pro-inflammatory cytokines in an equine endothelial cell (EEC) model at 10 hpi with either neuroviral or non-neuroviral strain of EHV-1. Similarly, studies from our laboratory have shown the ability of EHV-1 to produce type-I IFN induction in EECs as early as 3 hpi which is subsequently followed by a progressive decline by 6 and 12 hpi (Sarkar et al., 2015, 2016a,b; Oladunni et al., 2018, 2019). The initial upregulation of inflammatory cytokines during early EHV-1 infection helps to activate the adaptive arm of the host immune response toward eliminating the viral antigen. However, there is a concern that this response may be a double-edged sword: induced proinflammatory cytokines and activated coagulative responses that follow may also induce pathology that could negate their antiviral benefits.

It has also been reported that the host humoral immunity toward EHV-1 infection is temporary (van der Meulen et al., 2006) making horses susceptible to re-infection even after vaccination. EHV-1 infected horses usually display virus-neutralizing (VN) and complement-fixing (CF) antibodies within 2 weeks of infection (Hannant et al., 1993). This has proved important for early diagnosis of EHV-1 which is critical to quickly forestall the spread of infection to naïve, unexposed horses. While VN antibodies are type-specific and give longer protection (up to a year), there is cross-reactivity between CF antibodies of EHV-1 and EHV-4; however, CF antibodies only last for about 3 months. The host humoral immunity is usually targeted to recognize epitopes on the surface of envelope glycoproteins of EHV-1 (Allen and Yeargan, 1987; Crabb et al., 1991; Packiarajah et al., 1998; Perkins et al., 2019), and IgGa, IgGb, IgGc, IgGd, IgM, and IgG(T) antibody isotypes have all been detected in EHV-1-infected horses (Paillot et al., 2008; Wagner et al., 2015; Perkins et al., 2019). The protective effect of circulating antibodies during infection with EHV-1 is limited once a state of cell-associated viremia is established. However, local protection from freely circulating EHV-1 in the URT can be achieved with the help of mucosal antibody, particularly the IgA isotype. As a result, VN antibodies are helpful during the initial respiratory infection produced by EHV-1 but incompetent to provide protective immunity against the more severe sequelae: abortion and neurologic diseases which are enabled by the establishment of cell-associated viremia.

As with other intracellular pathogens, successful elimination of EHV-1 following the establishment of cell-associated viremia is dependent on an activated cytotoxic T lymphocyte (CTL) response. An upregulated CTL response has been reported following experimental EHV-1 infection (Breathnach et al., 2006) with IFN-γ playing a critical role in activating antigen-presenting cells and enhancing the antiviral effects of the circulating cytotoxic CD8 T cells. There is a relationship between the level/frequency of circulating CTL and protection from clinical signs of the diseases caused by EHV-1. Adult ponies with a previous history of exposure to EHV-1 produce high levels of EHV-1 specific circulating CTL and show fewer signs of clinical disease when compared to young ponies with low EHV-1 specific circulating CTL (O’Neill et al., 1999). This highlights the important role played by CTL precursor or memory cells during EHV-1 re-infection which may prove useful for testing the efficiency of EHV-1 vaccines in horses. The gene product of EHV-1 IEP encoded by ORF 64 has been reported to have epitopes specifically targeted by CTL from horses expressing the MHC class I A3/B2 serological haplotype (Soboll et al., 2003; Kydd et al., 2006). While this finding looks exciting for the development of vaccines for the immunodominant 95% population of Thoroughbred horses that express these serological haplotypes, further research is warranted to identify EHV-1 gene products expressed by other MHC class I haplotypes present in outbred horse populations.

### LABORATORY DIAGNOSIS

A rapid diagnosis of URTD associated with EHV-1 within a group of horses is highly desirable to aid therapeutic decisions and shape future control strategies to prevent an epidemic outbreak of the disease (Allen, 2002). Usually, the presenting clinical sign alone is not sufficient to reach a precise diagnosis as the initial clinical presentation may also resemble that of equine influenza, adenovirus, etc. As a result, laboratory diagnostic confirmation of EHV-1 induced URTD is predicated on the ability to detect the virus in submitted clinical materials. Polymerase chain reaction (PCR) is a useful diagnostic tool for an immediate identification/detection of genomic materials of
EHV-1 in submitted clinical or pathological samples such as aborted fetus, placenta, nasal swabs, nasal discharges, brain and spinal cord, paraffin-embedded archival tissues, and infected cell cultures (Ballagi-Pordany et al., 1990; Borchers and Slater, 1993; Kirisawa et al., 1993; Lawrence et al., 1994; Mackie et al., 1996). Perhaps the most sensitive diagnostic tool for EHM is the real-time PCR which can discriminate isolates possessing the single point mutation in the ORF30 gene associated with the neurologic phenotype of the disease (Smith et al., 2012). Evaluation of this newly improved real-time PCR revealed that it is more specific, besides being capable of discriminating an A<sub>2254</sub> from a G<sub>2254</sub>, than an old assay (Allen, 2007) that produces false dual positive results in detecting viral components in clinical samples. Allelic discrimination of viral nucleic acid during field outbreaks of EHV-1 is a useful epidemiological tool that allows for a rapid diagnosis and timely imposition of appropriate control measures required to prevent viral spread. It does not, of course, definitely diagnose EHM as the genetic correlation is not absolute as discussed above. One major caveat to the use of PCR is that it is not able to distinguish nucleic acid from a viable virus from that of a non-viable virus. It has been reported that the agreement between PCR and virus isolation is about 85–90 percent (Allen et al., 2004). This may be a particular concern when interpreting the presence of extremely low levels of viral DNA in clinical samples.

Direct detection of viral antigen from clinical samples using immunofluorescence staining also provides for rapid diagnosis of EHV-1. Detection of viral antigen in impression smears from nasopharyngeal swabs following fluorescent antibody staining can be used to demonstrate a positive EHV-1 infection (Allen, 2002; Allen et al., 2004). Immunohistochemically, EHV-1 antigens can be detected in paraffin-embedded tissues from infected horses using immunoperoxidase staining (Allen et al., 2004). Histopathological examination of paraffin-embedded tissue sections can also be employed to identify pathognomonic lesions typical of EHV-1 infections. However, these findings should also be verified by virus isolation from submitted clinical specimens.

Differential diagnosis of EHV-1 from cases of EHV-4 infection is difficult by serology. Using type-specific antigen, serological diagnostic tests such as enzyme-linked immunosorbent assay (ELISA), complement fixation (CF), and virus neutralization (VN) can be employed on paired serum samples to differentiate between EHV-1 and EHV-4. Serum samples that were taken during the acute and convalescent phases of infection can be screened to determine their titer; i.e., the highest dilution of sera with detectable binding/neutralization for either EHV-1/EHV-4. A type-specific ELISA assay, which detects distinct humoral response to a unique EHV-1/EHV-4 peptide antigen, has been developed and shown to be a valuable tool for a more accurate diagnosis (Lang et al., 2013).

The gold standard technique for a definitive diagnosis of EHV-1 is virus inoculation of cell cultures for isolation of the virus. EHV-1 can be isolated from various cell lines including those from the horse (EEC), rabbit (RK-13), monkey (Vero), and cattle (MDBK) (Allen et al., 2004; Rybachuk, 2009). The cytopathic effect (CPE), develops rapidly in cell cultures as clusters of rapidly enlarging, rounded, and detached cells which are characteristic of herpetic in appearance (Allen et al., 2004). The application of a quick diagnostic technique such as PCR in conjunction with virus culture and isolation is useful to characterize the virus for further epidemiological investigation. Confirmatory diagnosis of EHV-1 should rule out other differentials such as equine arteritis virus, influenza virus, adenovirus, rhinovirus, EHV-4, and Sarcocystis neurona infection, which may all present disease phenotypes that mimic EHV-1 infection.

**CURRENT TREATMENT AND CONTROL RECOMMENDATIONS**

There is no specific drug effective against EHV-1 disease conditions. However, good hygiene and management practices together with symptomatic treatment of infected horses may help curtail the spread of the viral infection. The current recommendations for treatment of recumbent horses include offering supportive care, nutritional care and rehydration, frequent bladder and rectal evacuation to prevent colic, and reduction of CNS inflammation (Wilson and Erickson, 1991; Goehring and Lunn, 2008). Symptomatic treatment with non-steroidal anti-inflammatory agents as an adjunct therapy may be helpful (Reed and Toribio, 2004; Lunn et al., 2009). Similarly, corticosteroids and immunomodulatory agents may be used to symptomatically treat early signs in cases of EHM. However, there is no evidence-based study to support the effectiveness of either drug class and caution must be applied not to reactivate virus shedding in latently infected horses (Lunn et al., 2009; Rybachuk, 2009). Corticosteroids are suggested to be protective against the cellular response to CNS infection thereby preventing the development of hemorrhage, edema, vasculitis, and thrombosis that are common early signs of EHM, and their use should be reserved for severe cases of EHM (Lunn et al., 2009).

Similarly, the administration of immunostimulants before horses are exposed to stressors could help prevent viral reactivation and replication but their value for treating EHV-1 infection is yet to be ascertained (Lunn et al., 2009). Antiviral drugs, especially virustatic agents like acyclovir derivatives, are theoretically beneficial for EHV-1 infection (Garré et al., 2007). Beside acyclovir, prophylactic administration of valacyclovir hydrochloride has been tried in experimentally infected horses with demonstrable benefits (Maxwell et al., 2017). Ganciclovir has been demonstrated to be the most potent inhibitor of EHV-1 infection in an in vitro study that investigated the efficacy of many antivirals against EHV-1 (Garré et al., 2007), and in a more recent study, it also offers a much-improved bioavailability, in vivo (Carmichael et al., 2013) compared to acyclovir.

Like other herpesviruses, EHV-1 infection is more complicated than most other viral infections; the establishment of persistent latent infection ensures that EHV-1 is naturally maintained in horse populations all year-round. Also, EHV-1 has evolved a vast array of strategies to avoid many components of the host innate and adaptive immune responses
As a result, an efficient EHV-1 vaccine must be able to invoke strong and sustained levels of humoral and cell-mediated immunity against the virus. In addition, since the establishment of cell-associated viremia is required for the development of abortion as well as EHM, an effective vaccine candidate must, also, be able to stimulate those immune responses needed to block the development of cell-associated viremia. The currently available commercial vaccines against EHV-1 in North America are in the form of inactivated whole virus vaccine and modified live vaccine (MLV). In a recent study, three groups of horses were either administered with a saline placebo or vaccinated with Rhinomune (Boehringer Ingelheim), derived from Rac-H strain (Mayr et al., 1968), or Pneumabort K-1B (Zoetis), which contains EHV-1 1P and 1B strains (Allen et al., 1985). The efficacy of either vaccine was then evaluated following an EHV-1 challenge experiment with the Findlay OH03 strain. Observed clinical signs of disease following infection with EHV-1 in the saline control group included pyrexia, depression, anorexia, coughing, nasal discharge, and dyspnea. Both the Rhinomune (Boehringer Ingelheim), an MLV, and Pneumabort K-1B (Zoetis), an inactivated vaccine, reduced the clinical incidence of disease with the former offering better protection (Goehring et al., 2010). However, the effectiveness of either vaccine in preventing EHV-1 induced abortion or EHM is still far from proven. EHV-1 antigen is also incorporated in some multivalent vaccines marketed across the US in their inactivated forms. Recombinant vaccine models expressing EHV-1 gB, gC, and gD reduced the initial nasal viral shedding in vaccines but offered less protection against cell-associated viremia and clinical signs of disease (Minke et al., 2006; Soboll et al., 2006). Intriguingly, a recombinant vaccine expressing an EHV-1 IE gene, encoded by ORF 64, significantly reduced cell-associated viremia in vaccinated ponies, however, its effect on EHV-1 induced abortion and EHM remain inconclusive (Soboll et al., 2010). There is currently no available vaccine that completely prevents EHV-1 infection, or EHV-1-induced cell-associated viremia or latency, and EHV-1 myeloencephalopathy has been reported in vaccinated horses (Kohn and Fenner, 1987; Wilson and Erickson, 1991; Friday et al., 2000; Henninger et al., 2007). Nonetheless, it is recommended to vaccinate every horse that is at risk of exposure to EHV-1 to help reduce the severity of EHV-1-related clinical manifestations. The updated version of American Association of Equine Practitioners (AAEP) guidelines for vaccination of adult horses provides a detailed recommendation for vaccinating against EHV-1 (Anonymous, 2015).

Control measures for curtailing EHV-1 infection are aimed at reducing viral dissemination to susceptible horses and also at preventing the reactivation of the virus in latently infected horses (Allen, 1986; Oslund et al., 1990; Oslund, 1993). Infected sick horses are primary sources of infectious EHV-1, and as such, should be quarantined to prevent direct contact with uninfected horses. Also, infected materials such as aborted fetus or uterine contents, including placenta, should be disposed of appropriately to curtail the spread of EHV-1 (Reed and Toribio, 2004). High-level biosecurity measures should be put in place in farms and all visitors should be encouraged to use a footbath and wash their hands before entering or leaving horse farms. Infected equipment must be disinfected and disposed of, and different equipment and workers must operate on affected and unaffected horses to prevent horizontal transmission of the disease (Allen, 1986). Movement of horses and visitors should be restricted onto and off the infected farm premises until laboratory tests indicate negative results for EHV-1 infection. Newly acquired horses should be quarantined from the rest of the herd for at least 3 weeks and must be certified negative for EHV-1 before being allowed to join the resident population. Horse owners and horse farmers should immediately report EHM outbreaks to relevant government agencies to contain the spread of the disease and to help formulate policies against future outbreaks.

CONCLUDING REMARKS

EHV-1 is still persistent among domesticated horses around the world and the vaccines currently available are not completely protective, especially against EHM. As a result, EHV-1 still poses a huge threat to the horse industry and efforts geared toward preventing the outbreak of the disease are strongly encouraged. Detailed information on both the host and certain environmental factors that enable the recent incidence of EHV-1 myeloencephalopathy are still elusive. Further research is required to determine robust epidemiological factors that promote the disease. Most research on how EHV-1 modulates host immune responses have been carried out in vitro with only a few studies investigating the immunomodulatory effects of EHV-1 in vivo. More in vivo studies focusing on viral properties that are important for the evasion of host immunity will help to expose putative therapeutic targets of EHV-1. Future progress in treatment and control of EHV-1 hinges on the combined application of detailed epidemiological data and in-depth knowledge of how the sophisticated viral biology promotes pathogenesis.

AUTHOR CONTRIBUTIONS

FO wrote the manuscript while both DH and TC edited it.

FUNDING

FO was supported by grant from the American Quarter Horse Association Young Investigator Award and by a fellowship from the Geoffrey C. Hughes Foundation. This work was supported in part by a grant from the Equine Drug Research Council of the Kentucky Horse Racing Commission. This work is a project of the Kentucky Agricultural Experiment Station (KY014053), supported by the National Institute of Food and Agriculture, U.S. Department of Agriculture, Animal Health Program.

ACKNOWLEDGMENTS

We thank Mr. Jamie Norris for his technical expertise with the use of Adobe Illustrator.
REFERENCES

Ackermann, M. (2006). Pathogenesis of gammaherpesvirus infections. Vet. Microbiol. 113, 211–222.

Allen, G. (1986). Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog. Vet. Microbiol. Immunol. 2, 78–144.

Allen, G. (2002). “Respiratory infections by equine herpesvirus types 1 and 4,” in Equine Respiratory Diseases, ed. P. Lekeux, (Ithaca, NY: International Veterinary Information Service).

Allen, G., Kydd, J., Slater, J., and Smith, K. (1999). “Advances in understanding the pathogenesis, epidemiology and immunological control of equid herpes-1 (EHV-1) abortion,” in Proceedings of the Eighth International Conference on Equine Infectious Diseases, eds U. Wernery, J. F. Wade, J. A. Mumford, and O. R. Kaaden, (Newmarket: R&W Publications Limited), 129–146.

Allen, G., Kydd, J., Slater, J., and Smith, K. (2004). Equid herpesvirus 1 and equid herpesvirus 4 infections. Infect. Dis. Livest. 2, 829–859.

Allen, G., Yearga, M., Turtinen, L., and Bryans, J. (1985). A new field strain of equine abortion virus (equine herpesvirus-1) among Kentucky horses. Am. J. Vet. Res. 46, 138–140.

Allen, G. P. (2007). Development of a real-time polymerase chain reaction assay for rapid diagnosis of neuropathogenic strains of equine herpesvirus-1. J. Vet. Diagn. Invest. 19, 69–72.

Allen, G. P., and Yearga, M. R. (1987). Use of lambda gt11 and monoclonal antibodies to map the genes for the six major glycoproteins of equine herpesvirus 1. J. Virol. 61, 2454–2461.

Anderson, K., and Goodpasture, E. W. (1942). Infection of newborn Syrian hamsters with the virus of mare abortion (Dimock and Edwards). Am. J. Pathol. 18, 555.

Anonymous (2005). National Economic Impact of the U.S. Horse Industry: Proceedings of the Eighth International Conference on Equine Virus Infections, eds U. Wernery, J. F. Wade, J. A. Mumford, and H. J. Rziha, (Dordrecht: Springer), 307–319.

Baxi, M., Efstathiou, S., Lawrence, G., Whalley, J., Slater, J., and Field, H. (1995). A present and future antiviral drug target. Trends Microbiol. 3, 741–745.

Bowles, D. E., Holden, V. R., Zhao, Y., and O’Callaghan, D. J. (1997). The ICp0 protein of equine herpesvirus 1 is an early protein that independently transactivates expression of all classes of viral promoters. J. Virol. 71, 4904–4914.

Bowles, D. E., Kim, S. K., and O’Callaghan, D. J. (2000). Characterization of the trans-activation properties of equine herpesvirus 1 ICp0 protein. J. Virol. 74, 1200–1208.

Broward, J. B., Visalli, R. J., Wilson, C. B., Loomis, J. S., Callahan, E. M., Courtney, R. J., et al. (2000). Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J. Virol. 74, 8692–8699.

Breathnach, C., Yearga, M., Timoney, J., and Allen, G. (2006). Detection of equine herpesvirus-specific effector and memory cytotoxic immunity in the equine upper respiratory tract. Vet. Immunol. Immunopathol. 111, 117–125.

Bryans, J. (1969). On immunity to disease caused by equine herpesvirus 1. J. Am. Vet. Med. Assoc. 155, 294–300.

Bryans, J., Crowe, M., Doll, E., and McCollum, W. (1957). Identification of a filterable agent causing arteritis of horses and abortion in mares; its differentiation from the equine abortion (influenza) virus. Cor. Vet. 47, 3–41.

Bryans, J., Swerczek, T., Darlington, R., and Crowe, M. (1977). Neonatal foal disease associated with perinatal infection by equine herpesvirus 1. Equine Med. Surg. 1, 20–26. doi: 10.1016/j.emer.2016.04.004

Bryans, J. T., and Allen, G. P. (1986). Equine viral rhinopneumonitis. Rev. Sci. Tech. 5, 837–847.

Buczynski, K. A., Kim, S. K., and O’Callaghan, D. J. (1999). Characterization of the transactivation domain of the equine herpesvirus type 1 immediate-early protein. Virus Res. 65, 131–140.

Burch, A. D., and Weller, S. K. (2005). Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. J. Virol. 79, 10740–10749.

Burges, B., Tokatloff, N., Manning, S., Lohmann, K., Lunn, D., Hussey, S., et al. (2012). Nasal shedding of equine Herpesvirus-1 from horses in an outbreak of equine herpesvirus myeloencephalopathy in Western Canada. J. Vet. Intern. Med. 26, 384–392.

Burrows, R., and Goodridge, D. (1984). “Studies of persistent and latent equid herpesvirus 1 and herpesvirus 3 infections in the Pibright pony herd,” in Latent Herpes Virus Infections in Veterinary Medicine, eds G. Wittmann, R. M. Gaskell, and H. J. Rziha, (Dordrecht: Springer), 307–319.

Caullé, A., Ugrinova, I., Epstein, A. L., Bouvet, P., Diaz, J.-J., and Greco, A. (2008). Nucleolin is required for an efficient herpes simplex virus type 1 infection. J. Virol. 82, 4762–4773. doi: 10.1128/JVI.00077-08

Carmichael, R., Whitfield, C., and Maxwell, L. J. (2013). Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. J. Vet. Pharmacol. Ther. 36, 441–449. doi: 10.1111/jvp.12029

Carrigan, M., Cosgrove, P., Kirkland, P., and Sabine, M. (1991). An outbreak of equid herpesvirus abortion in New South Wales. Equine Vet. J. 23, 108–110.

Caughman, G. B., Stazcek, J., and O’Callaghan, D. J. (1985). Equine herpesvirus type 1 infected cell polykaryocytes: evidence for immediate/early/late regulation of viral gene expression. Virology 145, 49–61.

Chang, Y. E., Van Sant, C., Krug, P. W., Sears, A. E., and Roizman, B. (1997). The null mutant of the U (L) 31 gene of herpes simplex virus 1: construction and phenotype in infected cells. J. Virol. 71, 8307–8315.

Chessers, P., Allsop, R., Purewal, A., and Edington, N. (1997). Detection of latency-associated transcripts of equine herpesvirus 1 in equine leukocytes but not in trigeminal ganglia. J. Virol. 71, 3437–3443.

Chi, H. J. I., Harley, C. A., Mukhopadhyay, A., and Wilson, D. W. (2005). The cytoplasmic tail of herpes simplex virus envelope glycoprotein D binds to the tegument protein VP22 and to capsids. J. Gen. Virol. 86, 253–261.

Copeland, A. M., Newcomb, W. W., and Brown, J. C. (2009). Herpes simplex virus replication: roles of viral proteins and nucleoporins in capsid-nucleus attachment. J. Virol. 83, 1660–1668. doi: 10.1128/JVI.01139-08

Couler, L., Moss, H., Lang, J., and McGeoch, D. (1993). A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted. J. Virol. 67, 331–336. doi: 10.1128/VI.67.1.331-336.1993

Cowan, A., and Goodpasture, E. W. (1942). Infection of newborn Syrian hamsters with the virus of mare abortion (Dimock and Edwards). Am. J. Pathol. 18, 555.

Coulter, L., Moss, H., Lang, J., and McGeoch, D. (1993). A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted. J. Virol. 67, 331–336. doi: 10.1128/VI.67.1.331-336.1993

Cowan, A., and Goodpasture, E. W. (1942). Infection of newborn Syrian hamsters with the virus of mare abortion (Dimock and Edwards). Am. J. Pathol. 18, 555.
Crabb, B. S., and Studdert, M. J. (1993). Epitopes of glycoprotein G of equine herpesviruses 4 and 1 located near the C termini elicit type-specific antibody responses in the natural host. J. Virol. 67, 6332–6338.

Crabb, B. S., and Studdert, M. J. (1995). Equine herpesviruses 4 (equine rhinopneumonitis virus) and 1 (equine abortion virus). Adv. Virus Res. 45, 153–192.

Crump, C. M., Bruun, B., Bell, S., Pomeranz, L. E., Minson, T., and Browne, H. M. (2004). Alpha herpesvirus glycoprotein M causes the relocation of plasma membrane proteins. J. Gen. Virol. 85, 3517–3527.

Davison, A., Eberle, R., Desrosiers, R. C., Fleckenstein, B., McGeoch, D. J., Pellet, P. E., et al. (2000). ‘Herpesviridae,’ in Proceeding of the Seventh Report of the International Committee on Taxonomy of Viruses, eds M. H. V. Van Regenmortel, et al. (Orlando, FL: Academic Press), 114–127.

Davison, A. J. (2007). ‘Overview of classification,’ in Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, eds A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whiteley, et al. (Cambridge: Cambridge University Press).

Davison, A. I. (2010). Herpesvirus systematics. Vet. Microbiol. 143, 52–69. doi: 10.1016/j.vetmic.2010.02.014

Davison, A. J., Eberle, R., Ehlers, B., Hayward, G. S., McGeoch, D. J., Minson, A. C., et al. (2009). The order herpesvirales. Arch. Virol. 154, 171–177. doi: 10.1007/s00705-008-0278-4

Del Piero, F., and Wilkins, P. A. (2001). Pulmonary vasculotropic EHV-1 infection in equids. Vet. Pathol. 38, 474.

Derbigy, W. A., Kim, S. K., Jang, H. K., and O’Callaghan, D. J. (2002). EHV-1 EICP22 protein sequences that mediate its physical interaction with the immediate-early protein are not sufficient to enhance the trans-activation activity of the IE protein. Virus Res. 84, 1–15.

Dimock, W. (1940). The diagnosis of virus infection in mares. J. Am. Vet. Med. Assoc. 96, 665–666.

Dimock, W., and Edwards, P. (1933). Is there a filterable virus of abortion in mares. J. A. M. A. 100, 1437–1439.

Donaldson, M. T., and Sweeney, C. R. (1997). Equine herpes myeloencephalopathy. Equ. Vet. J. 29, 864–871.

Dutta, S., and Myrup, A. (1983). Infectious center assay of intracellular virus and infective virus titer for equine mononuclear cells infected in vivo and in vitro with equine herpesviruses. Can. J. Comp. Med. 47, 64–69.

Edington, N., Bridges, C., and Huckle, A. (1985). Experimental reactivation of equid herpesvirus 1 (EHV 1) following the administration of corticosteroids. J. Comp. Pathol. 104, 379–387.

Edington, N., Welch, H., and Griffiths, L. (1994). The prevalence of latent equine herpesviruses in the tissues of 40 abattoir horses. Equ. Vet. J. 26, 140–142.

Elstathioiu, S., and Preston, C. (2005). Towards an understanding of the molecular basis of herpes simplex virus latency. Virus Res. 111, 108–119.

Elliott, G., and O’Hare, P. J. V. (1995). Equine herpesvirus 1 Gone 12, the functional homologue of herpes simplex virus VP16, transactivates via octamer sequences in the equine herpesvirus IE Gone promoter. Virology 213, 258–262.

Estell, K., Dawson, D., Magdesian, K., Swain, E., Laing, S., Siso, S., et al. (2015). Quantitative molecular viral loads in 7 horses with naturally occurring equine herpesvirus-1 infection. Equ. Vet. J. 47, 689–693. doi: 10.1111/ejv.12351

Everett, R. D., Freemont, P., Saitoh, H., Dasso, M., Orr, A., Kathoria, M., et al. (1998). The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72, 6581–6591.

Food and Agriculture Organization of the United Nations [FAOSTAT] (2017). Livestock, 2017: Rome: FAOSTAT.

Foote, C., Love, D., Gilkerson, J., and Whalley, J. (2004). Detection of EHV-1 and EHV-4 DNA in unwaned thoroughbred foals from vaccinated mares on a large stud farm. Equine Vet. J. 36, 341–345.

Forest, T., Barnard, S., and Baines, J. D. (2005). Active intranuclear movement of herpesvirus capsids. Nat. Cell Biol. 7, 429–431.

Frampton, A. R., Goins, W. F., Cohen, J. B., Von Einem, J., Osterrieder, N., O’Callaghan, D. J., et al. (2005). Equine herpesvirus 1 utilizes a novel herpesvirus entry receptor. J. Virol. 79, 3169–3173.

Frampton, A. R., Stolz, D. B., Uchida, H., Goins, W. F., Cohen, J. B., and Glorioso, J. C. (2007). Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1. J. Virol. 81, 10879–10889.

Franklin, T., Daft, B., Silverman, V., Powers, E., and Weidenbach, S. (1985). Serological titers and clinical observations in equines suspected of being infected with EHV-1. Calif. Vet. 39, 22–24.

Friday, P. A., Scarratt, W. K., Elvinger, F., Timoney, P. J., and Bonda, A. (2000). Ataxia and paralysis with equine herpesvirus type 1 infection in a herd of riding school horses. J. Vet. Intern. Med. 14, 197–201.

Fuchs, W., Klupp, B. G., Granzow, H., Hengartner, C., Brack, A., Mundt, A., et al. (2002a). Physical interaction between envelope glycoproteins E and M of pseudorabies virus and the major tegument protein UL49. J. Virol. 76, 8208–8217.

Fuchs, W., Klupp, B. G., Granzow, H., Osterrieder, N., and Mettenleiter, T. C. (2002b). The interacting UL31 and UL34 gene products of pseudorabies virus are involved in egress from the host-cell nucleus and represent components of primary enveloped but not mature virions. J. Virol. 76, 364–378.

Fukushi, H., Tomita, T., Taniguchi, A., Ochiai, Y., Kirisawa, R., Matsumura, T., et al. (1997). Gazelle herpes virus 1: a new neurotropic herpesvirus immunologically related to equine herpesvirus 1. Virology 227, 34–44.

Garko-Buczynski, K. A., Smith, R. H., Kim, S. K., and O’Callaghan, D. J. (1998). Complementation of a replication-defective mutant of equine herpesvirus type 1 by a cell line expressing the immediate-early protein. Virology 248, 83–94.

Garré, B., Van Der Meulen, K., Nugent, J., Neyts, J., Croubels, S., Da Bacco, P., et al. (2007). In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adenosine, PMEDAP and foscamet. Vet. Microbiol. 122, 43–51.

George, L. W. (1990). ‘Equine herpesvirus myeloencephalitis (rhinopneumonitis myelitis),’ in Large Animal Internal Medicine, ed. B. P. Smith, (St Louis, MO: CV Mosby), 913.

Gibson, J., O’Neill, T., Thackray, A., Hannant, D., and Field, H. (1992a). Serological responses of specific pathogen-free foals to equine herpesvirus-1: primary and secondary infection, and reactivation. Vet. Microbiol. 32, 199–214.

Gibson, J., Slater, I., Awan, A., and Field, H. (1992b). Pathogenesis of equine herpesvirus-1 in specific pathogen-free foals: primary and secondary infections and reactivation. Arch. Virol. 123, 351–366.

Gibson, J., Slater, I., and Field, H. (1992c). The pathogenicity of Ab4p, the sequenced strain of equine herpesvirus-1, in specific pathogen-free foals. Virology 189, 317–319.

Gillerson, J., Whalley, J., Drummer, H., Studdert, M., and Love, D. (1999). Epidemiological studies of equine herpesvirus 1 (EHV-1) in thoroughbred foals: a review of studies conducted in the Hunter Valley of New South Wales between 1995 and 1997. Vet. Microbiol. 68, 15–25.

Glessen, L., and Coggins, L. (1980). Response of pregnant mares to equine herpesvirus 1 (EHV1). Cor. Vet. 70, 391–400.
Goehringer, L., Wagner, B., Bigbie, R., Hussey, S., Rao, S., Morley, P., et al. (2010). Control of EHV-1 viremia and nasal shedding by commercial vaccines. *Vaccine* 28, 5203–5211. doi: 10.1016/j.vaccine.2010.05.065

Goehringer, L. S., and Lunn, D. P. (2008). “Equine herpesvirus myeloencephalopathy,” in *Current Therapy in Equine Medicine*, 6th Edn, eds N. E. Robinson, and K. Sprayberry, (St Louis, MO: Saunders), 77–181.

Gonnella, R., Farina, A., Santarelli, R., Raffa, S., Feederle, R., Rei, R., et al. (2005). Characterization and intracellular localization of the Epstein-Barr virus protein BFRF2: interactions with BFRF1 and with the nuclear lamina. *J. Virol. 79*, 3713–3727.

Goodman, L. B., Loregian, A., Perkins, G. A., Nugent, J., Buckles, E. L., Mercorelli, et al. (1991). An outbreak of foal perinatal mortality due to *Epstein-Barr virus*: life cycle and development of inhibitors. *Biochemistry* 30, 59–72.

Gray, W. L., Baumann, R. P., Robertson, A. T., Caughman, G. B., O'Callaghan, D. J., Granzow, H., Klupp, B. G., Fuchs, W., Veits, J., Osterrieder, N., and Mettenleiter, T. C. (2005). Entry of pseudorabies virus US3 protein on nuclear membrane localization of the UL34 protein and virus egress from the nucleus. *J. Gen. Virol.* 86, 263–267.

Huffman, J. B., Newcomb, W. B., Brown, J. C., and Homa, F. L. (2008). Amino acids 143 to 150 of the herpes simplex virus type 1 scaffold protein are required for the formation of portal-containing capsids. *J. Virol. 82*, 6778–6781. doi: 10.1128/JVI.00473-08

Hussey, S. G., Goehringer, L. S., Lunn, D. P., Hussey, S. B., Huang, T., Osterrieder, N., et al. (2013). Experimental infection with equine herpesvirus type 1 (EHV-1) induces chorioterional lesions. *Vet. Res. 44*:118. doi: 10.1186/1297-9411-44-118

Ivanovsky, D. (1882). Concerning the mosaic disease of the tobacco plant. *St. Petsb. Acad. Imp. Sci. Bul. 35*, 67–70. doi: 10.1016/j.jprot.2015.09.030

Jackson, T., and Kendrick, J. (1971). Paralysis of horses associated with equine herpesvirus 1 infection. *Am. V. Med. Ass. 158*, 1351–1357.

Jackson, T., Osburn, B., Cordy, D., and Kendrick, J. (1977). Equine herpesvirus 1 infection of horses: studies on the experimentally induced neurologic disease. *Am. J. Vet. Res. 38*, 709–719.

Johnstone, S., Barova, J., Campos, L., and Frampton, A. R. (2016). Equine herpesvirus type 1 modulates inflammatory host immune response genes in equine endothelial cells. *Vet. Microbiol. 192*, 52–59. doi: 10.1016/j.vetmic.2016.06.012

Kasem, S., Yu, M. H. H., Yamada, S., Kodaira, A., Matsumura, T., Tsjimura, K., et al. (2010). The ORF37 (UL24) is a neuropathogenic determinant of equine herpesvirus 1 (EHV-1) in the mouse encephalitis model. *Virology 400*, 259–270. doi: 10.1016/j.virol.2010.02.012

Kim, S. K., Bowles, D. E., and O'Callaghan, D. J. (1999). The γ2 late glycoprotein K promoter of equine herpesvirus 1 is differentially regulated by the IE and EICP0 proteins. *Virology 256*, 173–179.

Kisirisawa, R., Endo, A., Iwai, H., and Kawakami, Y. (1993). Detection and identification of equine herpesvirus-1 and-4 by polymerase chain reaction. *Vet. Microbiol. 36*, 57–67.

Klupp, B. G., Granzow, H., and Mettenleiter, T. C. (2000). Primary envelopment of pseudorabies virus at the nuclear membrane requires the UL34 gene product. *J. Virol. 74*, 10063–10073.

Klupp, B. G., Granzow, H., and Mettenleiter, T. C. (2001). Effect of the pseudorabies virus US3 protein on nuclear membrane localization of the UL34 protein and virus egress from the nucleus. *J. Gen. Virol.* 82, 2363–2371.

Kohn, C. W., and Fenner, W. R. (1987). Equine herpes myeloencephalopathy. *Vet. Clin. North Am. 3*, 405–419.

Kohn, C. W., Reed, S. M., Sofaly, C. D., Henninger, R. W., Saville, W. J., Allen, G. P., et al. (2006). Transmission of EHV-1 by horses with EHV-1 myeloencephalopathy: implications for biosecurity and review. *Clin. Tech. Equ. Pract. 5*, 60–66.

Kress, F. (1941). Virus abortus bei der Stute. *Wien. Tierarztl Wochenschr 28*, 320–322.

Kukhanova, M., Korovina, A., and Kochetkov, S. (2014). Human herpes simplex virus type 1 life cycle and development of inhibitors. *Biochemistry* 79, 1635–1652. doi: 10.1007/s00629-914310124

Kurtz, B. M., Singleton, L. B., Kelly, S. D., and Frampton, A. R. (2010). Equine caballus major histocompatibility complex class I is an entry receptor for equine herpesvirus type 1. *J. Virol. 84*, 9027–9034. doi: 10.1128/JVI.00287-10

Kydd, J. H., Davis-Poynter, N., Birch, J., Hannant, D., Minke, J., Audonnet, J.-C., et al. (2006). A molecular approach to the identification of cytotoxic T-lymphocyte epitopes within equine herpesvirus 1. *J. Gen. Virol.* 87, 2507–2515.

Kydd, J. H., Smith, K., Hannant, D., Livesay, G. J., and Mumford, J. A. (1994a). Distribution of equid herpesvirus-1 (EHV-1) in respiratory tract associated lymphoid tissue: implications for cellular immunity. *Eur. J. Vet. 26*, 470–473.

Kydd, J. H., Smith, K., Hannant, D., Livesay, G. J., and Mumford, J. A. (1994b). Distribution of Equid herpesvirus-1 (EHV-1) in the respiratory tract of ponies: implications for vaccination strategies. *Eur. J. Vet. 26*, 466–469.

Lang, A., de Vries, M., Feinse, S., Müller, E., Osterrieder, N., and Damiani, A. M. (2013). Development of a peptide ELISA for discrimination between serological responses to equine herpesvirus type 1 and 4. *J. Virol. Methods 193*, 667–673. doi: 10.1016/j.jviromet.2013.07.044

Lawrence, G., Gilkerson, J., Love, D., Sabine, M., and Whalley, J. (1994). Rapid, single-step differentiation of equid herpesviruses 1 and 4 from clinical material using the polymerase chain reaction and virus-specific primers. *J. Virol. Methods 47*, 59–72.
Lee, J. Y., Irmiere, A., and Gibson, W. (1988). Primate cytomegalovirus assembly: evidence that DNA packaging occurs subsequent to B capsid assembly. Virolology 167, 87–96.

Lewis, J. B., Thompson, Y. G., Feng, X., Holden, V. R., O'callaghan, D., and Caughman, G. B. (1997). Structural and antigenic identification of the ORF12 protein (oTIF) of equine herpesvirus 1. Virolology 230, 369–375.

Loomis, J. S., Courtney, R. J., and Wills, J. W. (2003). Binding partners for the UL11 tegument protein of herpes simplex virus type 1. J. Virol. 77, 11417–11424.

Lunn, D., Davis-Poynter, N., Flamino, M., Horohov, D., Osterrieder, K., Pusterla, N., et al. (2009). Equine herpesvirus-1 consensus statement. J. Vet. Intern. Med. 23, 450–461. doi: 10.1111/j.1939-1676.2009.03040.x

Lunn, D., Holmes, M., Gibson, J., Field, H., Kydd, J. H., and Duffus, W. (1991). Haematological changes and equine lymphocyte subpopulation kinetics during primary infection and attempted re-infection of specific pathogen free foals with EHV-1. Equ. Vet. J. 23, 35–40.

Luxtong, G. G., Haverlock, S., Coller, K. E., Antinone, S. E., Pincetic, A., and Smith, G. A. (2005). Targeting of herpesvirus capsid transport in axons is coupled to association with specific sets of tegument proteins. Proc. Natl. Acad. Sci. U.S.A. 102, 5832–5837.

Luxtong, G. G., Joy, I., Lee, H., Haverlock-Moyns, S., Schober, J. M., and Smith, G. A. (2006). The pseudorabies virus VP1/2 tegument protein is required for intracel lular capsid transport. J. Virol. 80, 201–209.

Ma, G., Feineis, S., Osterrieder, N., and Van de Walle, G. R. (2012). Identification and characterization of equine herpesvirus type 1 pUL56 and its role in virus-induced downregulation of major histocompatibility complex class I. J. Virol. 86, 3554–3563. doi: 10.1128/JVI.00994-11

Machtiger, N., Pancake, B., Eberle, R., Courtney, R., Tevethia, S., and Schaffer, P. (1980). Herpes simplex virus glycoproteins: isolation of mutants resistant to immune cytolysis. J. Virol. 34, 336–346.

Mackern, S., and Roizman, B. (1982). Structural features of the herpes simplex virus alpha gene 4, 0, and 27 promoter-regulatory sequences which confer alpha regulation on chimeric thymidine kinase genes. J. Virol. 44, 939–949.

Mackie, J., Macleod, G., Reubel, G., and Studdert, M. (1996). Diagnosis of equine herpesvirus 1 abortion using polymerase chain reaction. Aust. Vet. J. 74, 390–391.

Manningr, R. (1949). Studies on infectious abortion in mares due to a filterable virus. Acta Vet. Acad. Sci. Hungaricae 1, 62–69.

Manningr, R., and Coonents, J. (1941). Virabausorten der Stuten. Dtsch Tierartztl Wschr 49, 105–111.

Matsumura, T., Smith, R. H., and O'Callaghan, D. J. (1993). DNA sequence and organization of the genes coding for the major capsid proteins of equine herpesvirus-1. Virus Res. 230, 369–375.

Mumford, J. A., Hannant, D., Jessett, D. M., O'Neil, T., Smith, K. C., and Ostlund, E. N. (1994). “Equine infectious diseases VII,” in Proceedings of the Seventh International Conference on Equine Infectious Diseases, eds Abroughtig, et al. (New market: R&W Publications), 261–275.

Mumford, J. A., and Rossdale, P. (1980). Virus and its relationship to the “poor performace” syndrome. Equ. Vet. J. 12, 3–9.

Muranyi, W., Haas, J., Wagner, M., Krohne, G., and Koszinowski, U. H. (2002). Cytomegalovirus recruitment of cellular kinases to dissolve the nuclear lamina. Science 297, 854–857.

Muylaert, I., Tang, K.-W., and Elias, P. (2011). Replication and recombination of herpes simplex virus DNA. J. Biol. Chem. 286, 15619–15624.

Negussie, H., Gizaw, D., Tessema, T. S., and Nauwynck, H. (2017). Equine herpesvirus-1 myeloencephalopathy, an emerging threat of working equids in ethiopia. Transbound Emerg. Dis. 64, 389–397. doi: 10.1111/tbed.12377

Newcomb, W., Brown, J., Booy, F., and Steven, A. (1989). Nucleocapsid mass and capsomeric protein stoichiometry in equine herpesvirus 1: scanning transmission electron microscopic study. J. Virol. 63, 3777–3783.

Newcomb, W. W., Homa, F. L., Thomsen, D. R., Booy, F. P., Trus, B. L., Steven, A. C., et al. (1996). Assembly of the herpes simplex virus capsid: characterization of intermediates observed during cell-free capsid formation. J. Mol. Biol. 263, 432–446.

Newcomb, W. W., Thomsen, D. R., Homa, F. L., and Brown, J. C. (2003). Assembly of the herpes simplex virus capsid: identification of soluble scaffold-portal complexes and their role in formation of portal-containing capsids. J. Virol. 77, 9862–9871.

Nishiyama, Y. (2004). Herpes simplex virus gene products: the accessories reflect her lifestyle well. Rev. Med. Vet. 14, 33–46.

Nowotny, N., Burtscher, H., and Bürki, F. (1987). Neuropathogenicity for suckling mice of equine herpesvirus 1 from the Lipizaner outbreak 1983 and of selected other EHV 1 strains. J. Vet. Med. Ser. B 34, 441–448.

Nugent, J., Birch-Machin, I., Smith, K. C., Booy, F. P., Trus, B. L., Steven, A. C., et al. (2006). Analysis of equine herpesvirus-1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. J. Virol. 80, 4047–4060.

O'Callaghan, D. J., Gentry, G. A., and Randall, C. C. (1983). “The equine herpesviruses,” in The Herpesviruses, ed. B. Roizman, (Boston, MA: Springer), 215–318.

O'Callaghan, D. J., Henry, B. E., Wharton, J. H., Dauenhauer, S. A., Vance, R. B., Stacek, J., et al. (1981). “Equine herpesviruses: biochemical studies on genomic structure, DI particles, oncogenic transformation and persistent infection,” in Herpesvirus DNA, ed. Y. Becker, (Dordrecht: Springer), 387–418.

Ojala, P. M., Sodeik, B., Armati, P., and Cunningham, A. L. (2002). In the complex of two membranes. Curr. Opin. Microbiol. 6, 377–384.

Oladunni, F. S., Sarkar, S., Reedy, S., Balasuriya, U. B., Horohov, D. W., and Chambers, T. M. (2018). Absence of relationship between type-1 interferon suppression and neuropathogenicity of EHV-1. Vet. Immunol. Immunopathol. 197, 24–30. doi: 10.1016/j.vetimm.2018.01.007

Oladunni, F., Sarkar, S., Reedy, S., Balasuriya, U. B., Horohov, D. W., and Chambers, T. M. (2019). Equine herpesvirus type 1 targets the sensitization and induction steps to inhibit type-1 interferon response in equine endothelial cells. J. Virol. 93:e01342-19. doi: 10.1128/JVI.01342-19
mediated antiviral activity in equine endothelial cells. *Vet. Microbiol.* 183, 110–118. doi: 10.1016/j.vetmic.2015.12.011

Sasaki, M., Hasebe, R., Makino, Y., Suzuki, T., Fukushima, H., Okamoto, M., et al. (2011). Equine major histocompatibility complex class I molecules act as entry receptors that bind to equine herpesvirus-1 glycoprotein D. *Genes Cells* 16, 343–357. doi: 10.1111/j.1365-2443.2011.01491.x

Schumacher, D., Tischer, R. K., Trapp, S., and Osterrieder, N. (2005). The protein encoded by the US3 orthologue of Marek’s disease virus is required for efficient de-envelopment of perinuclear virions and involved in actin stress fiber breakdown. *J. Virol.* 79, 3987–3997.

Scott, J. C., Dutta, S., and Myrup, A. (1983). In vivo harboring of equine herpesvirus-1 in leukocyte populations and subpopulations and their quantitation from experimentally infected ponies. *Am. J. Vet. Res.* 44, 1344–1348.

Simpson-Holley, M., Colgrove, R. C., Nalepa, G., Harper, J. W., and Knipe, D. M. (2005). Identification and functional evaluation of cellular and viral factors involved in the alteration of nuclear architecture during herpes simplex virus 1 infection. *J. Virol.* 79, 12840–12851.

Singer, G. P., Newcomb, W. W., Thomsen, D. R., Homa, F. L., and Brown, J. C. (1982). Identification and molecular characterization of the envelope glycoproteins of equine herpesvirus-1. *J. Gen. Virol.* 63, 799–805.

Slater, J., Arnold, J., Taylor, K., Baxi, S., and Field, H. (1995). Fluorescein angiographic appearance of the normal fundus and of focal chorioretinal lesions required for interaction with the portal. *J. Virol.* 79, 132–139.

Slater, J., Arnold, J., Taylor, K., Baxi, S., and Field, H. (1995). Fluorescein angiographic appearance of the normal fundus and of focal chorioretinal lesions required for interaction with the portal. *J. Virol.* 79, 132–139.

Slater, J., Arnold, J., Taylor, K., Baxi, S., and Field, H. (1995). Fluorescein angiographic appearance of the normal fundus and of focal chorioretinal lesions required for interaction with the portal. *J. Virol.* 79, 132–139.

Slater, J., Arnold, J., Taylor, K., Baxi, S., and Field, H. (1995). Fluorescein angiographic appearance of the normal fundus and of focal chorioretinal lesions required for interaction with the portal. *J. Virol.* 79, 132–139.

Smolin, C., Schumacher, D., Tischer, R. K., Trapp, S., and Osterrieder, N. (2005). The protein encoded by the US3 orthologue of Marek’s disease virus is required for efficient de-envelopment of perinuclear virions and involved in actin stress fiber breakdown. *J. Virol.* 79, 3987–3997.

Taniuchi, A., Fukushima, H., Matsumura, T., Yanai, T., Masegi, T., and Hirai, K. (2000). Pathogenicity of a new neurotropic equine herpesvirus 9 (gazelle herpesvirus 1) in horses. *J. Vet. Med. Sci.* 62, 215–218.

Telford, E., Watson, M. S., Perry, J., Cullinane, A. A., and Davison, A. J. (1998). The DNA sequence of equine herpesvirus-4. *J. Gen. Virol.* 79, 1197–1203.

Telford, E. A., Watson, M. S., McBride, K., and Davison, A. J. (1992). The DNA sequence of equine herpesvirus-1. *Virology* 189, 304–316.

Timoney, P. (1992). *Rhinoencephalitis and Viral Abortion*. Veterinary Diagnostic Virology. St Louis, MO: Mosby Year Book Inc., 173–177.

Traub-Dargatz, J., Pelzel-McCluskey, A., Creekmore, L., Geiser-Novotny, S., Kasari, T., Wiedenheft, A., et al. (2013). Case-control study of a multistate equine herpesvirus myeloencephalopathy outbreak. *J. Vet. Intern. Med.* 27, 339–346. doi: 10.1111/jvim.12051

Tsuji, M., Iyama, T., Katayama, Y., Muranaka, M., Bannai, N., Nemoto, M., et al. (2011). Prevalence of equine herpesvirus type 1 strains of neuropathogenic genotype in a major breeding area of Japan. *Vet. Med. Sci.* 73, 1663–1667.

Turcotte, S., Letellier, J., and Lippé, R. (2005). Herpes simplex virus type 1 capsids transit by the trans-Golgi network, where viral glycoproteins accumulate independent of capsid egress. *J. Virol.* 79, 8847–8860.

Turtinen, L., Allen, G., Darlington, R., and Bryans, J. (1981). Serologic and molecular comparisons of several equine herpesvirus type 1 strains. *Am. J. Vet. Res.* 42, 2099–2104.

Turtinen, L. W. (1984). *A Review of EHV-1 Infection*. St Louis, MO: Mosby Year Book Inc., 173–177.

Turtinen, L. W. (1984). *A Review of EHV-1 Infection*. St Louis, MO: Mosby Year Book Inc., 173–177.

Turtinen, L. W. (1984). *A Review of EHV-1 Infection*. St Louis, MO: Mosby Year Book Inc., 173–177.

Weller, B., Goodman, L. B., Babasyan, S., Freer, H., Torsteinsdottir, S., Svansson, V., et al. (2010). Antibody and cellular immune responses following DNA vaccination and repeated vaccination with an inactivated equine herpesvirus vaccine. *Vaccine* 28, 3777–3785.

van der Meulen, K. M., Faveere, H. W., Pensaert, M. B., and Naouyck, H. (2006). Immune escape of equine herpesvirus 1 and other herpesviruses of veterinary importance. *Vet. Immunol. Immunopathol.* 111, 31–40.

van Galen, G., Leblond, A., Tritz, P., Martinelle, L., Pronost, S., and Saegerman, C. (2015). A retrospective study on equine herpesvirus type 1 associated myeloencephalopathy in France (2008–2011). *Vet. Microbiol.* 179, 304–309.

Vandekerckhove, A., Glerieux, S., Gryspeerdt, A., Steurers, L., Duchateau, L., Osterrieder, N., et al. (2010). Replication kinetics of neurovirulent versus non-neurovirus equine herpesvirus type 1 strains in equine nasal mucosal explants. *J. Gen. Virol.* 91, 2009–2028. doi: 10.1099/vir.0.019257-0

Vandekerckhove, A. P., Glerieux, S., Gryspeerdt, A., Steurers, L., Van Doorselaere, J., Osterrieder, N., et al. (2011). Equine alphaherpesviruses (EHV-1 and EHV-4) differ in their efficiency to infect mononuclear cells during early steps of infection in nasal mucosal explants. *Vet. Microbiol.* 152, 21–28. doi: 10.1016/j.vetmic.2011.03.038

Wagner, B., Goodman, L. B., Babasyan, S., Freer, H., Torsteinsdottir, S., Svensson, V., et al. (2015). Antibody and cellular immune responses of naive horses to repeated vaccination with an inactivated equine herpesvirus vaccine. *Vaccine* 33, 5588–5597. doi: 10.1016/j.vaccine.2015.09.009

Walter, J., Seeb, C., Fey, K., Bleul, U., and Osterrieder, N. (2013). Clinical observations and management of a severe equine herpesvirus type 1 outbreak with abortion and encephalomyelitis. *Acta Vet. Scand.* 55, 19. doi: 10.1186/1751-0475-19-55

Welch, H. M., Bridges, C. G., Lyon, A. M., Griffiths, L., and Edington, N. (1992). Latent equine herpesviruses 1 and 4: detection and distinction using the polymerase chain reaction and co-cultivation from lymphoid tissues. *J. Gen. Virol.* 73, 216–226.

Weller, S. K., and Coen, D. M. (2012). Herpes simplex viruses: mechanisms of DNA replication. *Cold Spring Harb. Perspect. Biol.* 4:a013011. doi: 10.1101/013011

Westerfield, C., and Dimock, W. (1946). The pathology of equine herpesvirus abortion. *Am. J. Vet. Res.* 7, 401–410.

Westerfield, C., and Dimock, W. (1946). The pathology of equine herpesvirus abortion. *Am. J. Vet. Res.* 7, 401–410.

Westerfield, C., and Dimock, W. (1946). The pathology of equine herpesvirus abortion. *Am. J. Vet. Res.* 7, 401–410.
Whalley, J. M., Robertson, G. R., and Davison, A. J. (1981). Analysis of the genome of equine herpesvirus type 1: arrangement of cleavage sites for restriction endonucleases EcoRI, BglII and BamHI. J. Gen. Virol. 57, 307–323.

Whitley, R. J., and Gnann, J. W. (1993). “The epidemiology and clinical manifestation of herpes simplex virus infections,” in The Human Herpesviruses, eds B. Roizman, R. J. Whitley, and C. Lopaz, (New York, NY: Raven Press), 69–105.

Whittaker, G. R., and Helenius, A. (1998). Nuclear import and export of viruses and virus genomes. Virology 246, 1–23.

Whitwell, K. E., and Blunden, A. (1992). Pathological findings in horses dying during an outbreak of the paralytic form of Equid herpesvirus type 1 (EHV-1) infection. Equ. Vet. J. 24, 13–19.

Wilson, J., and Erickson, D. (1991). Neurological syndrome of rhinopneumonitis. Proc. Am. Coll. Vet. Intern. Med. 9, 419–421.

Wilson, W. D. (1997). Equine herpesvirus 1 myeloencephalopathy. Vet. Clin. North Am. Equ. Pract. 13, 53–72.

Wolfstein, A., Nagel, C. H., Radtke, K., Döhner, K., Allan, V. J., and Sodeik, B. (2006). The inner tegument promotes herpes simplex virus capsid motility along microtubules in vitro. Traffic 7, 227–237.

Xie, Y., Wu, L., Wang, M., Cheng, A., Yang, Q., Wu, Y., et al. (2019). Alpha-herpesvirus thymidine kinase genes mediate viral virulence and are potential therapeutic targets. Front. Microbiol. 10:941. doi: 10.3389/fmicb.2019.00941

Yang, K., and Baines, J. D. (2008). Domain within herpes simplex virus 1 scaffold proteins required for interaction with portal protein in infected cells and incorporation of the portal vertex into capsids. J. Virol. 82, 5021–5030. doi: 10.1128/JVI.00150-08

Yang, K., Homa, F., and Baines, J. D. (2007). Putative terminase subunits of herpes simplex virus 1 form a complex in the cytoplasm and interact with portal protein in the nucleus. J. Virol. 81, 6419–6433.

Zhao, Y., Holdren, V., Harty, R. N., and O’Callaghan, D. J. (1992). Identification and transcriptional analyses of the UL3 and UL4 genes of equine herpesvirus 1, homologs of the ICP27 and glycoprotein K genes of herpes simplex virus. J. Virol. 66, 5363–5372.

Zhao, Y., Holdren, V. R., Smith, R. H., and O’Callaghan, D. J. (1995). Regulatory function of the equine herpesvirus 1 ICP27 gene product. J. Virol. 69, 2786–2793.

Zhou, Z. H., Chen, D. H., Jakana, J., Rixon, F. J., and Chiu, W. (1999). Visualization of tegument-capsid interactions and DNA in intact herpes simplex virus type 1 virions. J. Virol. 73, 3210–3218.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Oladunni, Horohov and Chambers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.